|
1
|
Zhu K, Guo Z, Zhang Y, Li S, Wang X, Xu R, Duan P. Latent profile analysis of emotional inhibition in older adults with gastrointestinal tumors: A cross-sectional study. Asia Pac J Oncol Nurs 2025; 12:100677. [PMID: 40144345 PMCID: PMC11937281 DOI: 10.1016/j.apjon.2025.100677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2024] [Accepted: 02/20/2025] [Indexed: 03/28/2025] Open
Abstract
Objective This study aimed to explore the current status of emotional inhibition in older adults with gastrointestinal tumors and to analyse its influencing factors. Methods From September to November 2024, 362 older adults with gastrointestinal tumors completed a self-designed questionnaire on demographic and clinical characteristics, an emotional inhibition scale, a self-esteem scale, and a multidimensional scale of perceived social support. Latent profile analysis was used to classify emotional inhibition in the participants, and multiple logistic regression was used to analyse the factors influencing each subgroup. Results Based on the level of emotional inhibition, older adults with gastrointestinal cancer were divided into three subgroups: "low emotional inhibition-active disclosure" (40.0%), "medium emotional inhibition" (41.2%), and "high emotional inhibition-disguise feelings group" (18.8%). The multivariate logistic regression analysis showed that sex, living conditions, disease stage, self-esteem level, and perceived social support were factors influencing participants' emotional inhibition (P < 0.05). Conclusions Emotional inhibition levels vary among older adults with gastrointestinal cancer. Medical staff should consider the characteristics, self-esteem, and perceived social support of the patients. Additionally, more targeted interventions, such as cognitive-behavioural group therapy or mindfulness-based cognitive therapy, should be developed to reduce patients' emotional inhibition.
Collapse
Affiliation(s)
- Kaili Zhu
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Zhangrong Guo
- Department of Orthopedics, The People's Hospital of Rugao, Nantong, China
| | - Yue Zhang
- Department of Nursing, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
| | - Siyu Li
- Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Xiaoqing Wang
- Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Rui Xu
- Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Peibei Duan
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
- Department of Nursing, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
|
2
|
Qin XJ, Kang MM, Zhong F, Liu JJ, Zhu ZC, Zhang D, Han K. Correlations of resilience with coping styles and quality of life in patients with malignancies. World J Psychiatry 2025; 15:100573. [DOI: 10.5498/wjp.v15.i4.100573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2024] [Revised: 01/23/2025] [Accepted: 02/13/2025] [Indexed: 03/25/2025] Open
Abstract
BACKGROUND Resilience is an individual’s ability and psychological rebound capacity to adapt well after experiencing adversity, trauma, etc. Patients with strong resilience can face illnesses actively.
AIM To determine the association of resilience with coping styles and quality of life in patients with malignancies.
METHODS This study included patients with malignant tumors who were hospitalized at Fuyang Hospital Affiliated to Anhui Medical University from March 2022 to March 2024. The Connor-Davidson Resilience Scale, Medical Coping Modes Questionnaire, Social Support Rating Scale, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were utilized to assess patients’ resilience, coping styles, social support, and quality of life, respectively. Pearson correlation analysis was conducted to assess the correlations.
RESULTS A total of 175 patients with malignant tumors demonstrated no marked difference in terms of age, education level, employment status, monthly household income, and disease staging (P < 0.05). Further, patients with malignancies demonstrated scores of 17.49 ± 1.20, 17.27 ± 1.46, and 11.19 ± 1.29 points in terms of coping styles in confrontation, avoidance, and resignation dimensions, respectively. Subjective support, objective support, and support utilization scores in terms of social support were 10.67 ± 1.80, 11.26 ± 2.08, and 9.24 ± 1.14 points, respectively. The total resilience score and tenacity, self-improvement, and optimism dimension scores were positively correlated with the confrontation coping style score, whereas the total resilience score and tenacity and self-improvement scores were negatively associated with avoidance and resignation coping style scores (P < 0.05). The total resilience score and the tenacity dimension score were positively associated with physical, role, cognitive, emotional, and social functions, as well as global health status (P < 0.05), and were inversely related to fatigue, insomnia, and economic difficulties (P < 0.05).
CONCLUSION The resilience of patients with malignancies is positively associated with the confrontation dimension in the coping style, the total and various social support domain scores, and the overall quality of life. Clinical medical staff need to pay attention to the effect of medical coping styles and social support on the resilience level of patients with malignancies to further improve their quality of life.
Collapse
Affiliation(s)
- Xue-Jin Qin
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Man-Man Kang
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Fei Zhong
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Jing-Jing Liu
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Zheng-Chun Zhu
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Di Zhang
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| | - Ke Han
- Department of Oncology, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang 236000, Anhui Province, China
| |
Collapse
|
|
3
|
Kim K, Yoon H. Effectiveness of a mobile-based return to work program for decent return to work, fatigue, stress, and quality of working life among cancer survivors. J Cancer Surviv 2025; 19:713-727. [PMID: 38769245 DOI: 10.1007/s11764-024-01570-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 03/13/2024] [Indexed: 05/22/2024]
Abstract
PURPOSE This study aimed to develop a smartphone mobile application-based supportive return to work (RTW) program for cancer survivors and evaluate its effects on their RTW, fatigue, stress, and quality of working life. This program was developed through a comprehensive process involving literature review, interviews with cancer survivors, and consultations with experts. METHODS A non-equivalent control group pre- and post-test design was used, with 41 participants assigned to the experimental (n = 18) and control (n = 23) groups based on recruitment timing. The experimental group received a 6-week smartphone mobile application-based supportive RTW program comprising "Counseling and Education" and "Self-Management." Participants completed assessments of decent RTW, fatigue, stress, and quality of working life at baseline and 6 months later. The experimental group completed an additional post-program completion survey. RESULTS During the 6-week program, no experimental group participants dropped out. The program's impact on decent RTW remains unclear. Fatigue (F = 2.52, p = 0.095) and quality of working life (F = 0.86, p = 0.434) did not show statistically significant differences. However, there was a significant reduction in stress (F = 4.59, p = 0.017). CONCLUSION The smartphone application-based RTW program, focusing on self-management and counseling, effectively reduced participants' stress levels. To further evaluate the effectiveness of the program, a more diverse range of interventions and ongoing programs should be implemented. IMPLICATIONS FOR CANCER SURVIVORS This study underscores the importance of tailored digital interventions to support the RTW of cancer survivors. The use of mobile smartphone applications allows temporal and spatial flexibility in program participation. Interventions involving various activities should be implemented to ensure ongoing participation.
Collapse
Affiliation(s)
- Kisook Kim
- Department of Nursing, Chung-Ang University, 84, Heukseok-Ro, Dongjak-Gu, Seoul, 06974, Republic of Korea
| | - Hyohyeon Yoon
- Department of Nursing, Chung-Ang University, 84, Heukseok-Ro, Dongjak-Gu, Seoul, 06974, Republic of Korea.
| |
Collapse
|
|
4
|
Yoon J, Kim H, Woo DH, Chae SY, Lee JH, Lee I, Lim I, Kim BI, Choi CW, Byun BH. F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study. Nucl Med Mol Imaging 2025; 59:117-124. [PMID: 40125026 PMCID: PMC11923350 DOI: 10.1007/s13139-024-00898-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2024] [Revised: 11/23/2024] [Accepted: 12/02/2024] [Indexed: 01/03/2025] Open
Abstract
Objectives To assess the trends and disparities in the utilization of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in Korea between 2018 and 2022, with a focus on disease classification, patient demographics, and regional distribution. Methods This national surveillance retrospective study uses data from the Health Insurance Review and Assessment Service (HIRA) database, which includes all FDG PET/CT examinations conducted in Korea from 2018 to 2022. Disease classifications, cancer types, age groups, gender, and geographic regions were analyzed using descriptive statistics. Utilization rates per 100,000 population were calculated for regional comparisons. Results FDG PET/CT utilization increased by 25.4%, from 174,885 examinations in 2018 to 219,377 in 2022. Older age groups (60 years and above) accounted for the majority of examinations, with males undergoing more examinations than females. Oncology remained the primary indication, with lung, colorectal, and non-Hodgkin lymphoma leading in examination numbers. The number of examinations performed on patients aged 60 and above increased at a higher rate compared to those under 60. Significant geographic disparities were found, with Seoul reporting the highest utilization rate (1,114.3 examinations per 100,000 population), while Gyeongbuk exhibited much lower rate (26.2 examinations per 100,000 population). Conclusions This study highlights the growing utilization of FDG PET/CT in Korea, particularly among older adults, with significant gender differences in cancer types. The findings also reveal disparities in FDG PET/CT utilization across regions, indicating varying access to advanced imaging technology.
Collapse
Affiliation(s)
- Jaesun Yoon
- Department of Biostatistics, Korea University, Seoul, Republic of Korea
| | - Heejin Kim
- Strategic Planning Team, Department of Strategic Planning and Coordination, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | - Do Hyun Woo
- Departments of Anesthesiology and Pain Medicine, Seoul, Republic of Korea
| | - Seung Yeop Chae
- Departments of Anesthesiology and Pain Medicine, Seoul, Republic of Korea
| | - Ji Heui Lee
- Departments of Anesthesiology and Pain Medicine, Seoul, Republic of Korea
| | - Inki Lee
- Departments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea Cancer Center Hospital, 75 Nowongil, Nowon Gu Seoul, 139-706 Republic of Korea
| | - Ilhan Lim
- Departments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea Cancer Center Hospital, 75 Nowongil, Nowon Gu Seoul, 139-706 Republic of Korea
| | - Byung Il Kim
- Departments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea Cancer Center Hospital, 75 Nowongil, Nowon Gu Seoul, 139-706 Republic of Korea
| | - Chang Woon Choi
- Departments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea Cancer Center Hospital, 75 Nowongil, Nowon Gu Seoul, 139-706 Republic of Korea
| | - Byung Hyung Byun
- Departments of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea Cancer Center Hospital, 75 Nowongil, Nowon Gu Seoul, 139-706 Republic of Korea
| |
Collapse
|
|
5
|
Li X, Wang Y, Ren M, Liu Q, Li J, Zhang L, Yao S, Tang L, Wen G, An J, Jin H, Tuo B. The role of chloride intracellular channel 4 in tumors. Cancer Cell Int 2025; 25:118. [PMID: 40140845 PMCID: PMC11948840 DOI: 10.1186/s12935-025-03737-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Accepted: 03/07/2025] [Indexed: 03/28/2025] Open
Abstract
Tumors are among the most predominant health problems in the world, and the annual incidence of cancer is increasing globally; therefore, there is an urgent need to identify effective therapeutic targets. Chloride intracellular channel 4 (CLIC4) belongs to the family of chloride intracellular channels (CLICs), which are widely expressed in various tissues and organs, such as the brain, lung, pancreas, colorectum, and ovary, and play important roles in promoting apoptosis, promoting angiogenesis, maintaining normal proliferation of endothelial cells, and regulating the assembly and reconstruction of the cytoskeleton. The expression and function of CLIC4 in tumors varies. It has been reported that CLIC4 is low expressed in gastric cancer, skin cancer and prostate cancer, suggesting a tumor suppressor role. Interestingly, CLIC4 is overexpressed in pancreatic, ovarian and breast cancers, indicating a cancer-promoting role. CLIC4 expression is dysregulated in some solid tumors, which may be because CLIC4 is involved in the growth, migration or invasion of some cancer cells through various mechanisms. Regulation of CLIC4 expression may be a potential therapeutic strategy for some tumors. CLIC4 may be a promising therapeutic target and a biomarker for some cancers. In this study, we review the role of CLIC4 in several cancers and its value in the diagnosis and treatment of tumors.
Collapse
Affiliation(s)
- Xin Li
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Yongfeng Wang
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Minmin Ren
- Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou Province, China
- Nursing School of Zunyi Medical University, Zunyi, 563003, Guizhou Province, China
| | - Qian Liu
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Jiajia Li
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Li Zhang
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Shun Yao
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Lulu Tang
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Guorong Wen
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Jiaxing An
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China
| | - Hai Jin
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China.
- The Collaborative Innovation Center of Tissue Damage Repair and Regenerative Medicine, Zunyi Medical University, Zunyi, 563003, China.
| | - Biguang Tuo
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, Guizhou, China.
- The Collaborative Innovation Center of Tissue Damage Repair and Regenerative Medicine, Zunyi Medical University, Zunyi, 563003, China.
| |
Collapse
|
|
6
|
Yan W, Liu M, Jing W, Kang L, Zhang N, Sun H, He J, Chen Z, Liu J, Liang W, Dong J. Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012-2021: a systematic analysis. Exp Hematol Oncol 2025; 14:38. [PMID: 40098177 PMCID: PMC11912769 DOI: 10.1186/s40164-025-00634-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2025] [Accepted: 03/06/2025] [Indexed: 03/19/2025] Open
Abstract
BACKGROUND The global cancer burden is rising, with early-onset cancers becoming more prevalent. We aimed to investigate the burden, trend and population disparity in 33 early-onset cancers from 2012 to 2021. METHODS Annual incidence, death, and disability-adjusted life years (DALY) numbers and rates for early-onset (15-49 years) cancer groups were calculated from Global Burden of Diseases (GBD) 2021 dataset, covering 2012-2021 across global, five SDI groupings, and 204 countries and territories. Estimated annual percentage change (EAPC) in the incidence, mortality and DALY rates was calculated to quantify temporal trends, while spearman correlation analysis was used to examine the correlation between rates, EAPC and SDI. RESULTS In 2021, there were 2.65 million new early-onset cancer cases excluding non-melanoma skin cancer (NMSC), resulting in 0.99 million deaths and 50.7 million DALYs. Breast, tracheal, bronchus and lung (TBL), cervical, colon and stomach cancers were the leading causes of DALYs. The DALY rate for early-onset cancer excluding NMSC changed from 65.7 million in 2012 to 67.0 million in 2021, with an estimated annual percentage change (EAPC) of -0.49%. While the DALY rate plateaued for females, it decreased by -0.95% for males. Ten of 33 cancer groups exhibited an EAPC > 0. The high SDI quintile had 1,100 DALYs per 100,000 caused by early-onset cancers excluding NMSC, with the highest declining trend in DALY and mortality rates, while the high-middle SDI quintile had the highest early-onset mortality rates. Rising trends in cancer incidence and mortality were especially notable among females in the middle, low-middle, and low SDI quintiles. CONCLUSION The global burden of early-onset cancer differs significantly by SDI quintile and gender. The increasing burden across multiple cancer groups poses a significant public health challenge. The rising burden of multiple cancer types is alarming, highlighting the need for increased policy support and targeted medical assistance to address the disparities in their impact.
Collapse
Affiliation(s)
- Wenxin Yan
- Vanke School of Public Health, Tsinghua University, Beijing, China
| | - Min Liu
- School of Public Health, Peking University, Beijing, China
| | - Wenzhan Jing
- Vanke School of Public Health, Tsinghua University, Beijing, China
- Department of Surgery, Asian Liver Center, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Liangyu Kang
- Vanke School of Public Health, Tsinghua University, Beijing, China
| | - Ning Zhang
- Vanke School of Public Health, Tsinghua University, Beijing, China
| | - Haoran Sun
- Vanke School of Public Health, Tsinghua University, Beijing, China
| | - Jinyu He
- Vanke School of Public Health, Tsinghua University, Beijing, China
| | - Zhongdan Chen
- World Health Organization Representative Office for China, Beijing, China
| | - Jue Liu
- School of Public Health, Peking University, Beijing, China.
| | - Wannian Liang
- Vanke School of Public Health, Tsinghua University, Beijing, China.
- Institute for Healthy China, Tsinghua University, Beijing, China.
| | - Jiahong Dong
- School of Clinical Medicine, Key Laboratory of Digital Intelligence, Hepatology (Ministry of Education), Tsinghua University, Beijing, China
| |
Collapse
|
|
7
|
Toivonen LA, Ponkilainen V, Repo JP, Mattila VM. Incidence of and survival after surgery for metastatic spine disease: a nationwide register-based study between 1997 and 2020 from Finland. Acta Orthop 2025; 96:250-255. [PMID: 40059767 PMCID: PMC11894730 DOI: 10.2340/17453674.2025.43264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Accepted: 02/21/2025] [Indexed: 03/14/2025] Open
Abstract
BACKGROUND AND PURPOSE Information on metastatic spine disease (MSD) based on nationwide data on trends and postoperative survival is limited but is needed to optimize treatment in this population. We aimed to assess the incidence of and survival rates after MSD surgery. METHODS This retrospective nationwide register-based study combined data from the Finnish Cancer Registry, Finnish Care Register for Health Care, and the Finnish Cause of Death Register from 1997 to 2020. Surgeries were identified using diagnosis and procedural codes, with primary spine pathologies excluded. Incidence rates were calculated per 100,000 inhabitants and adjusted for age and sex. Survival analysis was conducted using the Kaplan-Meier estimator. RESULTS 1,845 patients underwent 1,992 surgeries, with a mean age of 65 years; 58% were men. The most common primary cancers were prostate cancer (15.1%), breast cancer (11.6%), and myeloma (10.6%). The incidence of MSD surgery increased by 87%, from 1.05 to 1.97 per 100,000 person-years. Surgery increased most among patients aged 70-79 years. Over the same period, the 6-month survival remained fairly stable. The overall survival probabilities were 57% (95% confidence interval [CI] 54-59) at 1 year, 44% (CI 42-46) at 2 years, 28% (CI 26-30) at 5 years, and 18% (CI 16-20) at 10 years. The 1-year survival was highest in patients with breast cancer at 75% (CI 69-81) and lowest in patients with kidney cancer at 45% (CI 38-53) and prostate cancer at 47% (CI 42-53). CONCLUSION Finnish nationwide data showed an increase in MSD surgery between 1997 and 2020 with a stable postoperative survival of 57% (CI 48-69) to 76% (CI 66-89) at 6 months.
Collapse
Affiliation(s)
- Leevi A Toivonen
- Department of Orthopedics and Traumatology, Unit of Musculoskeletal Diseases, Tampere University Hospital and Tampere University, Tampere, Finland.
| | - Ville Ponkilainen
- Department of Orthopedics and Traumatology, Unit of Musculoskeletal Diseases, Tampere University Hospital and Tampere University, Tampere, Finland
| | - Jussi P Repo
- Department of Orthopedics and Traumatology, Unit of Musculoskeletal Diseases, Tampere University Hospital and Tampere University, Tampere, Finland
| | - Ville M Mattila
- Department of Orthopedics and Traumatology, Unit of Musculoskeletal Diseases, Tampere University Hospital and Tampere University, Tampere, Finland
| |
Collapse
|
|
8
|
Desai S, Aziz MK, Marmagkiolis K, Cilingiroglu M, Iliescu C, Ynalvez LA. Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer. Curr Cardiol Rep 2025; 27:65. [PMID: 40035980 DOI: 10.1007/s11886-025-02214-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/06/2025] [Indexed: 03/06/2025]
Abstract
PURPOSE OF REVIEW This review examines the current evidence and management strategies for stable coronary artery disease (CAD) and acute coronary syndrome (ACS) in patients with cancer. We outline the unique challenges, optimal treatment approaches, and outcomes in this growing population. RECENT FINDINGS First-line medications for CAD management are consistently underutilized in cancer patients despite serving as standard of care. As a corollary, medical optimization in CAD management in general is less likely to occur in patients with cancer. Early invasive strategies in ACS show improved survival, yet cancer patients receive percutaneous coronary intervention less frequently than non-cancer patients. Optimization of medical management should be prioritized in stable CAD; revascularization with PCI is first line for most patients presenting with ACS. Modification of risk factors contributing to both CAD and cancer is of utmost importance. Cancer survivors should receive vigilant, long-term monitoring for the development of signs of CAD.
Collapse
Affiliation(s)
- Shubh Desai
- Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
| | - Moez Karim Aziz
- Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | | | - Mehmet Cilingiroglu
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Cezar Iliescu
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
| | - Leslie A Ynalvez
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
|
9
|
Lop Gros J, Santiago Díaz P, Larrubia Loring M, Patriarca ME, Lloveras B, Iglesias M. Claudin 18.2 Immunohistochemistry Expression in Gastric Cancer: A Systematic Review. Appl Immunohistochem Mol Morphol 2025; 33:61-69. [PMID: 39894972 DOI: 10.1097/pai.0000000000001248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Accepted: 01/06/2025] [Indexed: 02/04/2025]
Abstract
Claudin 18.2 is a transmembrane protein, part of the tight-junction complex, selectively expressed in gastric epithelium. It is showing promising results as a target in advanced gastric cancer in phase 3 clinical trials using a monoclonal antibody against claudin 18.2. A systematic review on expression of claudin 18.2 in gastric cancer was performed using the PubMed database. The following search expression was used: ("Stomach Neoplasms" [Mesh]) AND (("claudin-18[TIAB]") OR ("CLDN18[TIAB]")). A total of n=99 articles were retrieved. Of those, 17 preclinical studies about claudin 18.2 expression by immunohistochemistry were selected. The results of those studies showed great variability in the criteria used for defining the thresholds for positivity of the stain. The proportion of claudin 18.2 positive cases varied between 24% and 83%. In works using a positivity threshold set at >40% or >70% of cells with membranous/cytoplasmic staining at 2+/3+ intensity, the average rate of positive cases was 50% or 30%, respectively (similar with clones 43-14A and EPR19202). Positivity of claudin 18.2 was associated with advanced stage, diffuse phenotype and PD-L1 and EBV positivity in some of the studies. Variability in criteria used to define claudin 18.2 positivity, as well as methodological differences, could explain the variation in the proportion of positive cases described, as well as the inconsistency of the association with clinical, molecular, and survival variables. The upcoming anticlaudin 18.2 therapy in advanced gastric cancer should prompt pathology laboratories to adjust their staining protocols and evaluation criteria in their series of patients, to further establish the association of claudin expression with clinical and molecular variables.
Collapse
Affiliation(s)
- Joan Lop Gros
- Department of Pathology, Hospital Clínic de Barcelona
| | | | | | | | - Belen Lloveras
- Department of Pathology, Hospital del Mar
- Hospital del Mar Research Institute
- Universitat Pompeu Fabra, Barcelona
| | - Mar Iglesias
- Department of Pathology, Hospital del Mar
- Hospital del Mar Research Institute
- Universitat Pompeu Fabra, Barcelona
- CIBERONC, Madrid, Spain
| |
Collapse
|
|
10
|
Moreno-Alonso D, Julià-Torras J, Majó Llopart J, Serrano-Bermúdez G, Duran Adán A, Pergolizzi D, Llorens-Torromé S, Trelis-Navarro J. The Catalan Institute of Oncology (ICO) Presents the ICO Toolkit-2: An Updated, Spanish National Assessment Kit for Patients with Malignant Neoplasm in Palliative Care. J Palliat Med 2025; 28:397-407. [PMID: 39728510 DOI: 10.1089/jpm.2024.0109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2024] Open
Abstract
Introduction: The needs of patients living with malignant neoplasm, and those of their families and care partners, require a multidimensional and interdisciplinary approach. By systematically assessing these needs with validated tools, healthcare professionals can identify and monitor therapeutic objectives, interventions, and results. Objective: At the Catalan Institute of Oncology (ICO), we set out to update the ICO Toolkit-a set of instruments for assessing the physical, emotional, and social needs of palliative care patients. Methods: We conducted a non-systematic review of the most common instruments currently used for multidimensional assessment of cancer patients nearing the end of life and then applied the Delphi method to achieve consensus on the instruments to be included in the updated ICO Toolkit-2. Initial consensus was obtained via interobserver agreement within a discussion group of experts, drawing on their daily clinical practice, and the published evidence. The Delphi method was then used to survey a representative sample of 22 experts from the ICO's three interdisciplinary palliative care teams. Results: The final 19 instruments selected for the ICO Toolkit-2 achieved a degree of consensus of 90%-100%. Conclusions: The updated ICO Toolkit-2 facilitates a multidimensional, systematic, objective, and measurable assessment of the needs of malignant neoplasm patients throughout their cancer journey. Uptake of the new toolkit could improve the care and support provided to patients and their families and care partners.
Collapse
Affiliation(s)
- Deborah Moreno-Alonso
- R+D, Palliative Care Service, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
- School of Medicine and Health Science, Universitat Internacional de Catalunya, Barcelona, Spain
- Universitat Internacional de Catalunya, Barcelona, Spain
| | - Joaquim Julià-Torras
- Universitat Internacional de Catalunya, Barcelona, Spain
- Palliative Care Service, Catalan Institute of Oncology, Badalona, Spain
| | | | - Gala Serrano-Bermúdez
- Palliative Care Service, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Anna Duran Adán
- Palliative Care Service, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Sílvia Llorens-Torromé
- Palliative Care Service, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jordi Trelis-Navarro
- Palliative Care Service, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
|
11
|
Li C, Zhang ED, Yu R, Yuan B, Yang Y, Zeng Z, Huang H. Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC. Transl Oncol 2025; 53:102314. [PMID: 39904279 PMCID: PMC11846587 DOI: 10.1016/j.tranon.2025.102314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 01/07/2025] [Accepted: 01/30/2025] [Indexed: 02/06/2025] Open
Abstract
BACKGROUND Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression. METHODS Explored CDC6 mRNA and protein expression in normal human tissues and tumors using TCGA, GTEx, and HPA. The role of CDC6 in cancer was analyzed using multiple web platforms and software, including R, cBioPortal, UALCAN, SangerBox and others. Finally, CCK-8, EdU assays and Transwell assays were used to verify the effects of CDC6 knockdown on HCC cell proliferation, migration, and invasion. RESULTS CDC6 expression was upregulated in most cancers and was associated with poorer prognosis. RNA methylation may play an important role in CDC6 epigenetic modification. CDC6 was significantly positively associated with CD4+ Th2 cells and MDSC in a variety of tumors. Furthermore, immunomodulatory genes are strongly associated with CDC6 expression in most tumor types. CDC6 has higher predictive value than B. Clonality and TMB, and its expression is significantly positively correlated with TMB/MSI and DNAss/RNAss, and is closely related to cell cycle events. Down-regulation of CDC6 can inhibit proliferation, migration and invasion of HCC cells. CONCLUSIONS CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies.
Collapse
Affiliation(s)
- Chenxuan Li
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China
| | - En-di Zhang
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China
| | - Rui Yu
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China
| | - Bo Yuan
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China
| | - Yunxin Yang
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China
| | - Zhong Zeng
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China.
| | - Hanfei Huang
- Organ Transplantation Center, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnnan, China.
| |
Collapse
|
|
12
|
Stephens A, Morrison C, Lutchka J, Richard C, Hares K, Tinsley S, Sood A, Shannon B, Rogers C, Shill J, Shakir N, Abdollah F. Prostate Cancer Screening and Diagnoses in the Transfeminine Population. Urology 2025; 197:80-87. [PMID: 39580118 DOI: 10.1016/j.urology.2024.11.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 10/31/2024] [Accepted: 11/15/2024] [Indexed: 11/25/2024]
Abstract
OBJECTIVE To examine the frequency and rate at which transfeminine patients receive prostate-specific antigen testing compared to a matched cisgender cohort. METHODS Patients with prostates who had encounters in our health system, are currently age 46 or older, and who are alive were included in our study. Transfeminine patients were identified through diagnosis codes and chart review. A 1:5 matched cohort was created based on patient age, race, and area deprivation index. Conditional logistic regression was done to compare odds of receiving any testing and Poisson regression was done to compare the total tests. RESULTS A total of 275,112 patients were included in the study, of which 315 were confirmed to be transfeminine. A well-matched 1:5 propensity-matched cohort was created. Our results suggest that transfeminine patients were 0.28 (95% CI 0.20-0.38, P <.001) times as likely as cisgender patients to receive at least 1 PSA test at our institution and received only 32% (95% CI 27%-37%, P <.001) as many total PSA tests. CONCLUSION Until more is known about the best practices for PSA testing in the transfeminine population, these patients should receive PSA testing. However, our results suggest that transfeminine patients are significantly less likely to receive any testing and significantly fewer tests in their lifetimes, which may represent a significant healthcare disparity.
Collapse
Affiliation(s)
- Alex Stephens
- Public Health Sciences, Henry Ford Health, Detroit, MI
| | | | | | - Caleb Richard
- Wayne State University School of Medicine, Detroit, MI
| | - Keinnan Hares
- Wayne State University School of Medicine, Detroit, MI
| | - Shane Tinsley
- Vattikuti Urology Institute & VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health, Detroit, MI
| | - Akshay Sood
- Department of Urology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH
| | - Briar Shannon
- Vattikuti Urology Institute & VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health, Detroit, MI
| | - Craig Rogers
- Vattikuti Urology Institute & VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health, Detroit, MI
| | - Jessica Shill
- Department of Endocrinology, Henry Ford Health, Detroit, MI
| | - Nabeel Shakir
- Vattikuti Urology Institute & VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health, Detroit, MI
| | - Firas Abdollah
- Vattikuti Urology Institute & VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health, Detroit, MI.
| |
Collapse
|
|
13
|
Liu WM, Chen CY, Ma HQ, Zhang QQ, Zhou X, Wu YL, Huang WJ, Qi XS, Zhang YX, Tang D, Sun HY, Wu HP, Jiao YF, He ZY, Yu WF, Yan HX. Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells. J Gastroenterol 2025:10.1007/s00535-025-02226-y. [PMID: 40019515 DOI: 10.1007/s00535-025-02226-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Accepted: 02/04/2025] [Indexed: 03/01/2025]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC), the most common form of liver cancer, presents a challenging malignancy with scarce treatment options. Liver progenitor cells (LPCs) play a pivotal role in both liver regeneration and the progression of liver cancer, yet the specific functions of LPCs from different origins in liver cancer remain to be fully elucidated. METHODS We explored the liver progenitor-like cells derived from human hepatocytes (HepLPCs) on the proliferation of HCC both in vitro and in vivo. The mitochondrial function was assessed through electron microscopy and functional experiments. Transcriptomic sequencing and western blot unveiled the fundamental mechanisms at play, whereas metabolomic sequencing pinpointed crucial effector molecules involved in the paracrine secretion of HepLPCs. RESULTS By employing a co-culture system of HepLPCs and HCC cells, we found that HepLPCs markedly inhibited HCC growth by prompting mitochondrial dysfunction, which further led to the co-inhibition of the Notch1 and JAK1/STAT3 signaling pathways through paracrine actions involving S-adenosylmethionine (SAM) and Nicotinic acid (NA). CONCLUSIONS This study has uncovered that HepLPCs have a suppressive influence on the proliferation of HCC cells. This is achieved through the impairment of mitochondrial function and the inhibition of key signaling pathways, namely, Notch1 and JAK1/STAT3, which are critical drivers of cancer progression. The secretion of the metabolites SAM and NA by HepLPCs appears to be instrumental in mediating these effects. These findings provide a solid foundation for identifying new therapeutic targets and clarifying the mechanisms through which HepLPCs can be harnessed to effectively treat HCC.
Collapse
Affiliation(s)
- Wen-Ming Liu
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Cai-Yang Chen
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Hong-Qian Ma
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Qiu-Qiu Zhang
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Xu Zhou
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yu-Ling Wu
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Wei-Jian Huang
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Xiao-Shu Qi
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yu-Xin Zhang
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Dan Tang
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Han-Yong Sun
- Department of Liver Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Hong-Ping Wu
- Department of Laboratory Medicine, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
| | - Ying-Fu Jiao
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China
| | - Zhi-Ying He
- Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
| | - Wei-Feng Yu
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China.
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China.
| | - He-Xin Yan
- Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, China.
- Shanghai Engineering Research Center of Peri-Operative Organ Support and Function Preservation (20DZ2254200), Renji Hospital, Shanghai, China.
| |
Collapse
|
|
14
|
Hu Y, Du Y, Qiu Z, Mao P, Da M. Identification and validation VAT1 in gastric cancer through bioinformatics and experimental analysis. Int Immunopharmacol 2025; 148:114047. [PMID: 39832459 DOI: 10.1016/j.intimp.2025.114047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2024] [Revised: 12/22/2024] [Accepted: 01/06/2025] [Indexed: 01/22/2025]
Abstract
This study investigated the expression pattern of Vesicular Amine Transporter 1 (VAT1) in gastric cancer (GC) and its impact on prognosis, alongside evaluating its potential as a biomarker for immunotherapy and chemotherapy. Analysis of transcriptomic data, supported by experimental validation, revealed that VAT1 is highly expressed in GC and is associated with poor prognosis. Kaplan-Meier and ROC analyses demonstrated VAT1's potential in GC diagnosis, while multivariate analysis confirmed its role as an independent risk factor. Gene set enrichment analysis indicated that VAT1 plays a role in regulating the MAPK signaling pathway and epithelial-mesenchymal transition (EMT) in GC. Immune infiltration analysis showed a positive correlation between VAT1 and immune cells, particularly macrophages, and a negative correlation with chemotherapy sensitivity. In vitro and in vivo experiments further confirmed VAT1's critical role in promoting GC cell proliferation and inhibiting apoptosis. Overall, VAT1 holds significant value not only in GC diagnosis and prognosis but also as a potential target for immunotherapy and overcoming drug resistance.
Collapse
Affiliation(s)
- Yongli Hu
- The First Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou 730000, China; Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
| | - Yan Du
- The Second Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou 730000, China.
| | - Zhisheng Qiu
- Department of Oncology Surgery, Gansu Provincial Hospital, Lanzhou 730000, China.
| | - Pengxue Mao
- Department of General Surgery, Minle County People's Hospital, Gansu Province 734500, China.
| | - Mingxu Da
- The First Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou 730000, China; Department of Oncology Surgery, Gansu Provincial Hospital, Lanzhou 730000, China.
| |
Collapse
|
|
15
|
Biesiada A, Ciałkowska-Rysz A, Babicki M, Kłoda K, Mastalerz-Migas A. The use of selected palliative medicine scales by family doctors in Poland, preliminary online study and its potential impact on knowledge dissemination. BMC MEDICAL EDUCATION 2025; 25:240. [PMID: 39953475 PMCID: PMC11829340 DOI: 10.1186/s12909-024-06594-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2024] [Accepted: 12/20/2024] [Indexed: 02/17/2025]
Abstract
BACKGROUND This study addresses the limited knowledge among Polish family doctors of scales for evaluating palliative care patients and their ability to assess symptoms using those scales. The aim was to identify the potential advantages and disadvantages for implementing this type of tools. METHODS A Computer-Assisted Web Interview (CAWI) was conducted among primary health care doctors. The survey assessed knowledge and usage of selected medical scales (KPS, ECOG, NRS, Barthel, Katz, ESAS, and a non-existent scale for bias check) in the daily practice of family physicians in relation to palliative care patients. RESULTS The study analysed responses from 706 doctors, revealing significant gaps in their knowledge and practical application of the scales. It presented lack of familiarity and inappropriate application of 4 out of 6 scales. Over 66% of surveyed doctors couldn't identify the appropriate tool for assessing the quality of life of patients with heart failure, and over 76% could not identify the appropriate tool for assessing shortness of breath and constipation. Based on the NRS pain scale this study indicates that knowledge of a scale translates directly to its practical application. CONCLUSIONS Appropriate educational activities should be provided to support GPs in broadening their knowledge and in using selected scales. Further studies need to be performed not only in the area of tools validation but simultaneously on how to disseminate the usage of those tools.
Collapse
Affiliation(s)
- Aleksander Biesiada
- Polish Society of Family Medicine, Wrocław, Poland.
- Soft&Med Family Medicine Practice, Kraków, Poland.
| | | | - Mateusz Babicki
- Polish Society of Family Medicine, Wrocław, Poland
- Department of Family Medicine, Piast of Silesia Medical University Wrocław, Wrocław, Poland
| | - Karolina Kłoda
- Polish Society of Family Medicine, Wrocław, Poland
- MEDFIT Karolina Kłoda, Szczecin, Poland
| | - Agnieszka Mastalerz-Migas
- Polish Society of Family Medicine, Wrocław, Poland
- Department of Family Medicine, Piast of Silesia Medical University Wrocław, Wrocław, Poland
| |
Collapse
|
|
16
|
Li T, Lin C, Wang W. Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021. BMC Cancer 2025; 25:189. [PMID: 39901108 PMCID: PMC11789343 DOI: 10.1186/s12885-025-13597-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Accepted: 01/24/2025] [Indexed: 02/05/2025] Open
Abstract
BACKGROUND The incidence and mortality rates of pancreatic cancer are rising globally. This study examines global and regional trends in pancreatic cancer incidence, Disability Adjusted Life Years (DALYs), and mortality from 1990 to 2021, utilizing data from the most recent Global Burden of Disease (GBD) 2021 database. METHODS Data were sourced from the GBD database over the period from 1990 to 2021. Age-standardized rates for incidence, DALYs, and mortality were calculated per 100,000 population. We also calculated the proportion of DALYs and mortality attributable to risk factors. The Bayesian age-period-cohort model was applied to project future trends until 2050. RESULTS Between 1990 and 2021, the global incidence of pancreatic cancer increased significantly, with the number of cases rising from approximately 207,905 to 508,533 and the age-standardized incidence rate (ASIR) increasing from 5.47 to 5.96 per 100,000 population. The global burden of pancreatic cancer, measured in DALYs, rose from 5.21 million to 11.32 million. Mortality rates showed a similar upward trend, with the number of deaths increasing from around 211,613 to 505,752, and the age-standardized mortality rate (ASMR) rising from 5.655 to 5.948 per 100,000 population. Notable increases in ASIR and ASMR were observed in low-middle and low sociodemographic index regions with males experienced higher rates compared to females. Age-standardized DALYs rate (ASDR) and ASMR worldwide were attributable to tobacco smoking, high BMI, and high fasting plasma glucose. Furthermore, our projection model estimates that the ASIR and ASMR of pancreatic cancer will significantly decline, while the ASDR is anticipated to maintain a steady downward trend by 2050. CONCLUSION This study offers a comprehensive analysis of pancreatic cancer trends, providing crucial insights for public health planning and policy-making. Addressing identified risk factors and targeting high-risk populations are essential for effective strategies to reduce the global burden of pancreatic cancer.
Collapse
Affiliation(s)
- Tianyu Li
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Chen Lin
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| | - Weibin Wang
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| |
Collapse
|
|
17
|
Tang C, He Q, Xiong Y, Chen Z. Safety and Effectiveness of Drug-Eluting Embolic Bronchial Arterial Chemoembolization for Lung Cancer: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol 2025; 36:221-236.e8. [PMID: 39477084 DOI: 10.1016/j.jvir.2024.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 09/26/2024] [Accepted: 10/19/2024] [Indexed: 12/19/2024] Open
Abstract
PURPOSE To assess the effectiveness and safety of drug-eluting embolic (DEE) bronchial arterial chemoembolization (BACE) in lung cancer and compare its outcomes with those of conventional BACE (cBACE). MATERIALS AND METHODS A comprehensive search was conducted across PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, and Wanfang databases. Random-effects model analysis was applied when I2 was ≥50%; otherwise, fixed-effects model analysis was used. Subgroup analysis was performed for I2 values of ≥50%. Eighteen studies involving 681 patients were included, with 501 patients receiving DEE-BACE and 110 patients undergoing cBACE. RESULTS Among patients with lung cancer treated with DEE-BACE, the pooled objective response rates (ORRs) at 1 and 6 months were 64.4% and 50.3%, respectively; the disease control rates (DCRs) at 1, 3, and 6 months were 93.4%, 74.4%, and 71.7%, respectively. The 1-year overall survival and progression-free survival rates were 48.2% and 22.5%, respectively. The incidences of adverse events such as cough, fever, chest discomfort, nausea, fatigue, and leukopenia were reported at 30.7%, 22.8%, 22.4%, 29.6%, 7.4%, and 21.8%, respectively. Compared with the cBACE group, the DEE-BACE group exhibited higher 1-month DCR (pooled relative risk [RR], 1.236; 95% confidence interval [CI], 1.028-1.486) and 6-month ORR (pooled RR, 2.036; 95% CI, 1.226-3.383) and DCR (pooled RR, 1.824; 95% CI, 1.249-2.662). Both DEE-BACE and cBACE exhibited similar rates of adverse events. CONCLUSIONS DEE-BACE presents a favorable effectiveness and safety profile for lung cancer treatment compared with cBACE, particularly for nonresectable cases or when chemotherapy or radiation therapy options are limited. However, the lack of direct comparisons with standard treatments requires cautious interpretation of these results.
Collapse
Affiliation(s)
- Congsheng Tang
- Department of Respiratory Medicine, Haining People's Hospital, Zhejiang, China
| | - Qifan He
- Department of Radiology, Haining People's Hospital, Zhejiang, China
| | - Yue Xiong
- Department of Radiology, Haining People's Hospital, Zhejiang, China
| | - Zhonghua Chen
- Department of Radiology, Haining People's Hospital, Zhejiang, China.
| |
Collapse
|
|
18
|
Tran MJ, Jefford M, Fua T, Smith B, McDowell L, Dhillon HM, Lynch F, Shaw J, White A, Wiesenfeld D, McNally O, Ftanou M. Feasibility and Acceptability of the Fear-Less Screening and Stratified-Care Model for Fear of Cancer Recurrence Among People Affected by Early-Stage Cancer. Psychooncology 2025; 34:e70070. [PMID: 39953998 PMCID: PMC11829655 DOI: 10.1002/pon.70070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 11/07/2024] [Accepted: 12/31/2024] [Indexed: 02/17/2025]
Abstract
OBJECTIVES Fear of cancer recurrence (FCR) is a prevalent unmet need for people affected by cancer, in the context of limited healthcare resources. Stratified-care models have potential to meet this need, while reducing resource demands. This study aimed to evaluate the feasibility and acceptability of screening procedures and interventions within the Fear-Less stratified-care model among those impacted by early-stage cancer. METHODS People affected by breast, head and neck, or gynaecological cancer, who had completed curative treatment, were screened for FCR. Individuals experiencing moderate FCR (scored 13-21 on the Fear of Cancer Recurrence Inventory-Short Form; FCRI-SF) were offered a purpose-developed clinician-guided self-management intervention, while those experiencing severe FCR (FCRI-SF score ≥ 22) were offered individual therapy (ConquerFear). Re-screening and evaluation measures were completed post-intervention. RESULTS Seventy-six (70%) of 109 eligible people completed screening, with 53/76 participating in the Fear-Less model evaluation. Thirty-nine of 53 participants reported FCR and were referred to an intervention; 30/39 (77%) accepted the referral. Fifteen (83%) of 18 participants completing the self-management intervention reported reading ≥ 75% of the resource at 5 weeks, with 10/18 (56%) reporting clinically meaningful (≥ 10%) reductions on the FCRI-SF post-intervention. Qualitative feedback indicated screening and the stratified-care received were acceptable. CONCLUSIONS Screening procedures and interventions forming the Fear-Less model appear feasible and acceptable for identifying and treating FCR among people affected by early-stage cancer. Although further research is required to evaluate its efficacy, this model has the potential to meet a major unmet need, where psychosocial services are limited amid increased demand. TRIAL REGISTRATION This study was retrospectively registered on the Australian New Zealand Clinical Trials Registry (ACTRN12622000818730) on 10/6/2022.
Collapse
Affiliation(s)
- Mei Jun Tran
- Psychosocial Oncology ProgramPeter MacCallum Cancer CentreVictoriaAustralia
| | - Michael Jefford
- Department of Health Services ResearchPeter MacCallum Cancer CentreVictoriaAustralia
- Australian Cancer Survivorship CentrePeter MacCallum Cancer CentreVictoriaAustralia
- Sir Peter MacCallum Department of OncologyThe University of MelbourneVictoriaAustralia
| | - Tsien Fua
- Sir Peter MacCallum Department of OncologyThe University of MelbourneVictoriaAustralia
- Department of Radiation OncologyPeter MacCallum Cancer CentreVictoriaAustralia
| | - Ben Smith
- The Daffodil CentreThe University of SydneyA Joint Venture with Cancer Council NSWSydneyAustralia
- Ingham Institute for Applied Medical ResearchSouth West Sydney Clinical CampusesUNSW Medicine & HealthUniversity of New South WalesLiverpoolAustralia
| | - Lachlan McDowell
- Department of Radiation OncologyPeter MacCallum Cancer CentreVictoriaAustralia
- Department of Radiation OncologyPrincess Alexandra HospitalWoolloongabbaAustralia
| | - Haryana M. Dhillon
- School of PsychologyFaculty of SciencePsycho‐Oncology Cooperative Research GroupThe University of SydneySydneyAustralia
| | - Fiona Lynch
- Psychosocial Oncology ProgramPeter MacCallum Cancer CentreVictoriaAustralia
- Psychology DepartmentAndrew Love Cancer CentreBarwon HealthVictoriaAustralia
| | - Joanne Shaw
- School of PsychologyFaculty of SciencePsycho‐Oncology Cooperative Research GroupThe University of SydneySydneyAustralia
| | - Alan White
- Consumer RepresentativePeter MacCallum Cancer CentreMelbourneAustralia
- Consumer RepresentativeProstate Cancer Foundation of AustraliaSydneyAustralia
| | - David Wiesenfeld
- Victorian Comprehensive Cancer CentreLead in Head and Neck Research and EducationVictoriaAustralia
- Oral and Maxillofacial SurgeonThe Royal Melbourne Hospital and Peter MacCallum Cancer CentreVictoriaAustralia
| | - Orla McNally
- Director Oncology/DysplasiaRoyal Women's HospitalVictoriaAustralia
- The University of MelbourneVictoriaAustralia
- Director Gynaecology Tumour StreamVictorian Comprehensive Cancer Centre and Peter MacCallum Cancer CentreVictoriaAustralia
| | - Maria Ftanou
- Psychosocial Oncology ProgramPeter MacCallum Cancer CentreVictoriaAustralia
- Melbourne School of Population and Global HealthThe University of MelbourneVictoriaAustralia
| |
Collapse
|
|
19
|
Rutkowski K, Gola M, Godlewski J, Starzyńska A, Marvaso G, Mastroleo F, Giulia Vincini M, Porazzi A, Zaffaroni M, Jereczek-Fossa BA. Understanding the role of nerves in head and neck cancers - a review. Oncol Rev 2025; 18:1514004. [PMID: 39906323 PMCID: PMC11791411 DOI: 10.3389/or.2024.1514004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2024] [Accepted: 12/03/2024] [Indexed: 02/06/2025] Open
Abstract
Worldwide, head and neck cancers (HNCs) account for approximately 900,000 cases and 500,000 deaths annually, with their incidence continuing to rise. Carcinogenesis is a complex, multidimensional molecular process leading to cancer development, and in recent years, the role of nerves in the pathogenesis of various malignancies has been increasingly recognized. Thanks to the abundant innervation of the head and neck region, peripheral nervous system has gained considerable interest for its possible role in the development and progression of HNCs. Intratumoral parasympathetic, sympathetic, and sensory nerve fibers are emerging as key players and potential targets for novel anti-cancer and pain-relieving medications in different tumors, including HNCs. This review explores nerve-cancer interactions, including perineural invasion (PNI), cancer-related axonogenesis, neurogenesis, and nerve reprogramming, with an emphasis on their molecular mechanisms, mediators and clinical implications. PNI, an adverse histopathologic feature, has been widely investigated in HNCs. However, its prognostic value remains debated due to inconsistent results when classified dichotomously (present/absent). Emerging evidence suggests that quantitative and qualitative descriptions of PNI may better reflect its clinical usefulness. The review also examines therapies targeting nerve-cancer crosstalk and highlights the influence of HPV status on tumor innervation. By synthesizing current knowledge, challenges, and future perspectives, this review offers insights into the molecular basis of nerve involvement in HNCs and the potential for novel therapeutic approaches.
Collapse
Affiliation(s)
- Krzysztof Rutkowski
- Department of Hematology, Transplantology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Michał Gola
- Department of Human Histology and Embryology, Collegium Medicum, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland
- Department of Oncology and Immuno-Oncology, Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre, Olsztyn, Poland
| | - Janusz Godlewski
- Department of Human Histology and Embryology, Collegium Medicum, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland
- Department of Surgical Oncology, Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre, Olsztyn, Poland
| | - Anna Starzyńska
- Department of Oral Surgery, Medical University of Gdańsk, Gdańsk, Poland
- Department of Otolaryngology, Phoniatrics and Audiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
| | - Giulia Marvaso
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Federico Mastroleo
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Maria Giulia Vincini
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Alice Porazzi
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - Mattia Zaffaroni
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - Barbara Alicja Jereczek-Fossa
- Division of Radiation Oncology, European Institute of Oncology (IEO), Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
|
20
|
Zhang N, He Z, Qin X, Han K, Zhu Z, Zhong F. Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy. Discov Oncol 2025; 16:55. [PMID: 39832113 PMCID: PMC11747051 DOI: 10.1007/s12672-025-01801-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2024] [Accepted: 01/13/2025] [Indexed: 01/22/2025] Open
Abstract
BACKGROUND Centromere protein N (CENPN), located on chromosome 16q23.2, encodes vital nucleosome-associated complexes that are essential for dynamic assembly processes. CENPN plays a pivotal role in regulating cell proliferation and cell cycle progression by influencing mitotic events. Despite its potential importance, the precise functional role and regulatory mechanisms of CENPN in diverse malignancies remain largely unexplored. This study aimed to elucidate the role of CENPN in human cancers and evaluate its prognostic significance. METHODS Investigate the role of CENPN in various malignancies, we leveraged data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. We employed a comprehensive suite of web platforms and software tools for data analysis, including R, Cytoscape, an integrated repository portal for tumor-immune system interactions (TISIDB), CBio Cancer Genomics Portal (cBioPortal), Search Tool for the Retrieval of Interaction Gene/Proteins (STRING), Gene Set Cancer Analysis (GSCALite), and a cancer single-cell state atlas (CancerSEA). RESULTS The findings demonstrated that CENPN expression was elevated in the majority of cancer types and differentially expressed across molecular and immune subtypes. Functional enrichment analysis in multiple tumors also identified possible pathways of CENPN involvement in tumorigenesis. Its expression positively correlated with Th2 and Tcm cells in most cancers. It is also correlated with genetic markers of immunomodulators in various cancers. CONCLUSIONS Overall, CENPN expression is closely related to cancers and has the potential to act as a cancer biomarker.
Collapse
Affiliation(s)
- Nie Zhang
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China
- Graduate School of Anhui Medical University, Hefei, China
- Key Laboratory of Gametes and Abnormal Reproductive Tract of National Health Commission, Anhui Medical University, Hefei, China
| | - Zhuoying He
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China
- Graduate School of Anhui Medical University, Hefei, China
| | - Xuejin Qin
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China
| | - Ke Han
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China
| | - Zhengchun Zhu
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China
| | - Fei Zhong
- Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, 236000, China.
- Key Laboratory of Gametes and Abnormal Reproductive Tract of National Health Commission, Anhui Medical University, Hefei, China.
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
| |
Collapse
|
|
21
|
Simoni AH, Ahlstrøm LMV, Ording AG, Iversen LH, Johnsen SP, Jensen JW, Møller H. Quality indicators and development targets in the national clinical quality registries in cancer care and screening. BMJ Open Qual 2025; 14:e003019. [PMID: 39755562 PMCID: PMC11751976 DOI: 10.1136/bmjoq-2024-003019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2024] [Accepted: 12/17/2024] [Indexed: 01/06/2025] Open
Abstract
BACKGROUND The Danish clinical quality registries monitor and improve the quality of care, using quality indicators and defined development targets referred to as 'standards'. This study aims to investigate the fulfilment of standards in the Danish clinical quality registries in cancer care and screening. METHODS Data was included from annual reports in the 27 Danish clinical quality registries in cancer care and screening. The most recent report from each registry was downloaded the 13 December 2023. Indicators were included if: evaluating care or screening over 12 months, presenting a well-defined standard with a desired direction and presenting the proportion and number of individuals for which the standard was fulfilled. Data were extracted on national and regional levels for the last 3 years, and fulfilment of standards was presented as the proportion of indicators that fulfilled the standard within each unit of comparison. RESULTS In total, 216 quality indicators were included. At the national and regional level, standards were fulfilled for 75% and 71%, respectively. Fulfilment within the registries varied from 5% to 100% on national and 12% to 99% on regional level. Standards were more often fulfilled for result (than process indicators) and for established (than supplemental indicators). Altogether, 43% of the standards were fulfilled across all regions delivering data for the specific indicator. CONCLUSIONS The approach to defining standards for clinical quality indicators as conservative minimum or ambitious development targets varied in the Danish clinical quality registries in cancer care and screening. This deviating behaviour seriously restrains possibilities for comparing clinical quality across cancers despite the robust infrastructure of the quality registries, limiting the possibilities for overview and prioritising resources and attention to the most urgent cancers.
Collapse
Affiliation(s)
- Amalie Helme Simoni
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | - Anne Gulbech Ording
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Lene Hjerrild Iversen
- Department of Surgery, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Søren Paaske Johnsen
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Jens Winther Jensen
- The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark
| | - Henrik Møller
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark
| |
Collapse
|
|
22
|
Jabbour J, Dandache R, Al Slaybe M, Mattar LH, Rizk R. Suboptimal dietary knowledge predicts lower diet quality for cancer prevention among university students in Beirut. PLoS One 2025; 20:e0315911. [PMID: 39752540 PMCID: PMC11698321 DOI: 10.1371/journal.pone.0315911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Accepted: 12/03/2024] [Indexed: 01/06/2025] Open
Abstract
University students are at a pivotal stage of shaping cancer risk factors. Little is known about their dietary behavior in Lebanon, a country heavily burdened by cancer. This cross-sectional study assessed the dietary knowledge of and adherence to cancer prevention guidelines among university students in Beirut, Lebanon. We hypothesized that students would exhibit low knowledge, poor diet quality, and that knowledge predicted diet quality. Dietary knowledge was explored using a dedicated questionnaire, with scores above the 60th percentile considered as Knowledgeable (Kn+), and those below as less knowledgeable (Kn-). Dietary adherence to cancer prevention guidelines and the predictors of the Alternative Healthy Eating Index (AHEI)- a measure of diet quality calculated using the Modified Mediterranean Prime Screen, were also examined. The sample included 300 participants (55% females, mean age: 20 years). The mean knowledge score was 49.5%. Over 50% of students were aware of the association between red and processed meat, sodium, fruits and vegetables, obesity, and cancer. Kn+ group had a higher intake of vegetables and a lower intake of meats and sweetened beverages. Increased knowledge (B = 0.78, 95%CI: 0.18,1.37) and high physical activity (B = 4.62, 95%CI: 1.66,7.59) were associated with elevated AHEI scores. A significant positive interaction was observed between knowledge and enrollment in a health-related major. University students' dietary knowledge of and adherence to cancer prevention guidelines are suboptimal. Although higher knowledge predicts high-quality diets, the association was weak. Further studies should investigate the food systems influencing university students' dietary intake of university students in Lebanon and identify effective interventions to enhance health behavior.
Collapse
Affiliation(s)
- Jana Jabbour
- Department of Nutrition and Food Science, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
| | - Rodeina Dandache
- Department of Nutrition and Food Science, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
| | - Maryam Al Slaybe
- Department of Nutrition and Food Science, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
| | - Lama Haisam Mattar
- Department of Nutrition and Food Science, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
| | - Rana Rizk
- Department of Nutrition and Food Science, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon
- Institut National de Santé Publique, d’Epidémiologie Clinique, et de Toxicologie (INSPECT-LB), Lebanon
| |
Collapse
|
|
23
|
Hiyoshi A, Alexanderson K, Tinghög P, Cao Y, Fall K, Montgomery S. Future sick leave, disability pension, and unemployment among patients with cancer after returning to work: Swedish register-based matched prospective cohort study. Cancer 2025; 131:e35580. [PMID: 39377486 PMCID: PMC11694158 DOI: 10.1002/cncr.35580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 08/10/2024] [Accepted: 09/04/2024] [Indexed: 10/09/2024]
Abstract
INTRODUCTION Despite increasing numbers of working-age cancer survivors, evidence on their future work-related circumstances is limited. This study examined their future sick leave, disability pension, and unemployment benefits compared to matched cancer-free individuals. METHODS A matched cohort study was conducted using nationwide Swedish registers. In total, 94,411 individuals aged 25 to 59 years when diagnosed with incident cancer in 2001-2012 and who returned to work after cancer were compared with their matched cancer-free individuals (N = 354,814). Follow-up started from the year before cancer diagnosis and continued up to 14 years. Generalized estimating equations were used to calculate incidence rate ratios (IRR) and odds ratios for the difference between cancer survivors and matched cancer-free individuals. RESULTS Compared with cancer-free individuals, cancer survivors had six times higher sick-leave days per year after cancer (IRR 6.25 [95% CI, 5.97-6.54] for men; IRR, 5.51 [5.39-5.64] for women). This higher number of sick-leave days declined over time but a two-fold difference persisted. An approximate 1.5 times higher risk of receiving disability pension remained during follow-up. The unemployment days tended to be lower for cancer survivors (IRR, 0.84 [0.75-0.94] for men; IRR, 0.91 [0.86-0.96] for women). Risk of sick leave and disability pension was higher among those with leukemia, colorectal, and breast cancer than skin and genitourinary cancers. CONCLUSIONS Cancer survivors who returned to work experienced a high and persisting sick leave and disability pension for over a decade. Prolonged receipt of a high amount of benefits may have long-term adverse impacts on financial circumstances; more knowledge to promote the environment that encourages returning to and remaining in work is needed.
Collapse
Affiliation(s)
- Ayako Hiyoshi
- Clinical Epidemiology and BiostatisticsSchool of Medical SciencesFaculty of Medicine and HealthÖrebro UniversityÖrebroSweden
- Department of Public Health SciencesStockholm UniversityStockholmSweden
| | - Kristina Alexanderson
- Division of Insurance MedicineDepartment of Clinical NeuroscienceKarolinska InstitutetStockholmSweden
| | - Petter Tinghög
- Division of Insurance MedicineDepartment of Clinical NeuroscienceKarolinska InstitutetStockholmSweden
- Department of Health SciencesRed Cross University CollegeStockholmSweden
| | - Yang Cao
- Clinical Epidemiology and BiostatisticsSchool of Medical SciencesFaculty of Medicine and HealthÖrebro UniversityÖrebroSweden
- Integrative EpidemiologyInstitute of Environmental MedicineKarolinska InstitutetStockholmSweden
| | - Katja Fall
- Clinical Epidemiology and BiostatisticsSchool of Medical SciencesFaculty of Medicine and HealthÖrebro UniversityÖrebroSweden
- Integrative EpidemiologyInstitute of Environmental MedicineKarolinska InstitutetStockholmSweden
| | - Scott Montgomery
- Clinical Epidemiology and BiostatisticsSchool of Medical SciencesFaculty of Medicine and HealthÖrebro UniversityÖrebroSweden
- Clinical Epidemiology DivisionDepartment of MedicineSolnaKarolinska InstitutetStockholmSweden
- Department of Epidemiology and Public HealthUniversity College LondonLondonUK
| |
Collapse
|
|
24
|
Kumar P, Kinger S, Dubey AR, Jagtap YA, Choudhary A, Karmakar S, Lal G, Kumar A, Bhattacharyya S, Poluri KM, Mishra A. Ketorolac disturbs proteasome functions and induces mitochondrial abnormality-associated apoptosis. IUBMB Life 2025; 77:e2937. [PMID: 39723629 DOI: 10.1002/iub.2937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2024] [Accepted: 12/11/2024] [Indexed: 12/28/2024]
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended to treat moderate-to-severe pain. Previous studies suggest that NSAIDs can suppress cellular proliferation and elevate apoptosis in different cancer cells. Ketorolac is an NSAID and can reduce the cancer cells' viability. However, molecular mechanisms by which Ketorolac can induce apoptosis and be helpful as an anti-tumor agent against carcinogenesis are unclear. Here, we observed treatment with Ketorolac disturbs proteasome functions, which induces aggregation of aberrant ubiquitinated proteins. Ketorolac exposure also induced the aggregation of expanded polyglutamine proteins, results cellular proteostasis disturbance. We found that the treatment of Ketorolac aggravates the accumulation of various cell cycle-linked proteins, which results in pro-apoptotic induction in cells. Ketorolac-mediated proteasome disturbance leads to mitochondrial abnormalities. Finally, we have observed that Ketorolac treatment depolarized mitochondrial membrane potential, released cytochrome c into cytoplasm, and induced apoptosis in cells, which could be due to proteasome functional depletion. Perhaps more in-depth research is required to understand the details of NSAID-based anti-proliferative molecular mechanisms that can elevate apoptosis in cancer cells and generate anti-tumor potential with the combination of putative cancer drugs.
Collapse
Affiliation(s)
- Prashant Kumar
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Sumit Kinger
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Ankur Rakesh Dubey
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Yuvraj Anandrao Jagtap
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Akash Choudhary
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Surojit Karmakar
- National Centre for Cell Science (NCCS), Pune, Maharashtra, India
| | - Girdhari Lal
- National Centre for Cell Science (NCCS), Pune, Maharashtra, India
| | - Amit Kumar
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, Madhya Pradesh, India
| | - Sudipta Bhattacharyya
- Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| | - Krishna Mohan Poluri
- Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand, India
| | - Amit Mishra
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India
| |
Collapse
|
|
25
|
Avagimyan A, Kakturskiy L, Pogosova N, Ottaviani G, Rizzo M, Sarrafzadegan N. Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: Review of preclinical model. Curr Probl Cardiol 2025; 50:102882. [PMID: 39427867 DOI: 10.1016/j.cpcardiol.2024.102882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2024] [Accepted: 10/08/2024] [Indexed: 10/22/2024]
Abstract
Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) - Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive.
Collapse
Affiliation(s)
- Ashot Avagimyan
- Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
| | - Lev Kakturskiy
- A.P. Avtsyn Research Institute of Human Morphology, Petrovskiy NRCS, Moscow, Russia
| | - Nana Pogosova
- National Medical Research Centre of Cardiology after acad. E. I. Chazov, Moscow, Russia; Peoples' Friendship University of Russia after Patrice Lumumba (RUDN), Moscow, Russia
| | - Giulia Ottaviani
- Lino Rossi Research Center, Università degli Studi di Milano, Milan, Italy
| | | | - Nizal Sarrafzadegan
- Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; University of British Columbia, Vancouver, Canada
| |
Collapse
|
|
26
|
Xu B, Yan Y. The Association Between IL-8 Gene Polymorphisms and the Risk of Several Types of Cancer, Especially in Gastric Cancer. Cancer Rep (Hoboken) 2025; 8:e70103. [PMID: 39821721 PMCID: PMC11740087 DOI: 10.1002/cnr2.70103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2024] [Revised: 11/25/2024] [Accepted: 12/13/2024] [Indexed: 01/19/2025] Open
Abstract
BACKGROUND Changes in functional genetic polymorphisms may increase or decrease the risk of cancer in patients. Nowadays, the association between polymorphisms in the interleukin-8 (IL-8) gene and the susceptibility of cancer risk have been investigated in many studies, however, above relationships remain unclear. AIM The current study aims to comprehensively evaluate the association between IL-8 gene six polymorphisms and the whole cancer risk, especially -251 polymorphism and gastric cancer. METHODS AND RESULTS Six polymorphisms (-251, -353, +678, +1633, +2767, +781) were collected. The expression of serum IL-8 was calculated by ELISA assay. First, 104 case-control studies were conducted. Second, this research has made significant discoveries regarding the -251, -353 and +781 polymorphisms and the potential associations with cancer risk. Finally, the serum IL-8 levels in gastric cancer patients with AA/TT genotypes were significantly higher than those with the same genotypes of healthy controls and TT genotypes in gastric cancer patients. CONCLUSION Overall, the investigation has revealed that IL-8 gene polymorphisms significantly influence vulnerability to cancer development, especially for gastric cancer.
Collapse
Affiliation(s)
- Bin Xu
- Geriatrics DepartmentAffiliated Hospital of Jiangnan UniversityWuxiChina
| | - Yidan Yan
- Medical OncologyAffiliated Hospital of Jiangnan UniversityWuxiChina
| |
Collapse
|
|
27
|
Ferri GM, De Maria L, Delvecchio G, Caputi A, Sole S, Giannelli G, Sifanno G, Di Somma IM, Pentimone F, Cavone D, Stufano A, Lovreglio P, Ricci V, Vimercati L. Standardized Mortality Ratios (SMRs) and Radon Exposure Analysis for Lung Cancer and All-Cause Mortality in Locorotondo, Southern Italy. MEDICINA (KAUNAS, LITHUANIA) 2024; 61:47. [PMID: 39859029 PMCID: PMC11766524 DOI: 10.3390/medicina61010047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 12/18/2024] [Accepted: 12/26/2024] [Indexed: 01/27/2025]
Abstract
Background and Objectives: Radon is a known risk factor for lung cancer, and residential radon exposure is the leading cause of lung cancer in never smokers; however, in Italy, there is still a lack of public awareness regarding the risk caused by residential radon exposure. In this mortality study, which was carried out in an Italian Apulian town (Locorotondo) of the Bari province, we aimed to analyze lung cancer mortality and all-cause mortality in a population highly exposed to radon. Materials and Methods: The study period was 1998-2021. Local and Italian population and national mortality data were collected from the Italian National Institute of Statistics (ISTAT) website platform. Local mortality data were collected using copies of the Local Health Authority death certificates. Results: We identified 117 lung cancers in the studied period. The mortality data trends revealed a decrease in the all-causes standardized mortality ratios (SMRs), increases in the incidence rates of lung cancer and colorectal cancer in recent years, and a decrease in the incidence of noncancer diseases. We also found high SMRs for colorectal cancer until 2016 among older females. With respect to the cardio-circulatory system, only in 2014 did the male SMRs significantly influence the total SMR; after this period, a decreasing stable trend was observed. Conclusions: The natural balance of the population is decreasing, and mortality is decreasing for all causes. A future study will be needed to assess the associations between observed lung cancer cases and domestic radon exposure to drive radon mitigation and public health strategies.
Collapse
Affiliation(s)
- Giovanni Maria Ferri
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Luigi De Maria
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Giuseppe Delvecchio
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Antonio Caputi
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Stefano Sole
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Gianmarco Giannelli
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Gianfranco Sifanno
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Ilaria Maria Di Somma
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Floriana Pentimone
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Domenica Cavone
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Angela Stufano
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Piero Lovreglio
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| | - Vitantonio Ricci
- Prevention Department, Local Health Authority Bari, Viale Bari, 28, 70011 Alberobello, Italy;
| | - Luigi Vimercati
- Interdisciplinary Department of Medicine, University of Bari, Piazza G. Cesare, 11, 70124 Bari, Italy; (G.M.F.); (L.D.M.); (G.D.); (A.C.); (S.S.); (G.G.); (G.S.); (I.M.D.S.); (F.P.); (D.C.); (A.S.); (P.L.)
| |
Collapse
|
|
28
|
Anderson T, Prue G, Graham-Wisener L, McLaughlin S, Mitchell G. Exploring the supportive care needs of families affected by pancreatic cancer: a mixed-methods study protocol. BMC Cancer 2024; 24:1540. [PMID: 39696068 DOI: 10.1186/s12885-024-13335-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2024] [Accepted: 12/11/2024] [Indexed: 12/20/2024] Open
Abstract
BACKGROUND Pancreatic cancer is an aggressive disease with most cases diagnosed at an advanced stage resulting in low survival rates. Family members often take on a role of supporting patients' needs. Families tend to be unprepared for this and experience high levels of unmet needs and substantial impacts to their own wellbeing, heightened by the rapid deterioration and short life expectancy associated with pancreatic cancer. AIM The proposed study aims to explore the supportive care needs and associated psychosocial impact of pancreatic cancer on family members, and the role of support services in supporting these families. METHODS A sequential explanatory mixed methods design will be utilised. Data collection will consist of three phases: (1) Survey of affected family members to explore their supportive care needs and psychological wellbeing; (2) Semi-structured interviews to explore the lived experiences of family members across the disease trajectory, their psychosocial adjustment, and their perceptions of support services; (3) Focus groups with support services providers to explore their experiences in providing support to affected families. DISCUSSION By combining quantitative and qualitative approaches, this research aims to provide a comprehensive understanding of the challenges and opportunities in providing psychosocial support to families affected by pancreatic cancer, ultimately enhancing their quality of life during and after the cancer journey. The findings may help to inform the development and enhancement of support programs, tailored to meet the specific needs of affected families.
Collapse
Affiliation(s)
- Tara Anderson
- School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
| | - Gillian Prue
- School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK
| | | | | | - Gary Mitchell
- School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK
| |
Collapse
|
|
29
|
Adessi TG, Centurión EFG, Horra CDL, Chocan C, Bajicoff S, Blank V, Roguin L, Riveira MJ. Concise Three Step Synthesis of the Bioactive Alkaloid Huajiaosimuline via a Zn(OTf) 2-Promoted Meinwald Rearrangement. Chem Biodivers 2024:e202402680. [PMID: 39620903 DOI: 10.1002/cbdv.202402680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2024] [Revised: 11/29/2024] [Accepted: 12/02/2024] [Indexed: 12/28/2024]
Abstract
The synthesis of the biologically active alkaloid huajiaosimulne, isolated from the roots of Zanthoxylum simulans, is reported. The natural product was assembled from simple commercial reagents via initial domino Knoevenagel/oxa-6π-electrocyclization followed by epoxidation and an epoxide/ketone rearrangement promoted by Zn(OTf)2. In vitro cytotoxicity assays identified natural products huajiaosimuline and simulansine as moderate antiproliferative agents against murine colon cancer CT26 cells.
Collapse
Affiliation(s)
- Tonino G Adessi
- Instituto de Química Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario-CONICET, Rosario, Argentina
| | - Enzo F G Centurión
- Instituto de Química Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario-CONICET, Rosario, Argentina
| | - Camila De La Horra
- Instituto de Química Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario-CONICET, Rosario, Argentina
| | - Camila Chocan
- Laboratorio de Oncología y Transducción de Señales, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Sofía Bajicoff
- Laboratorio de Oncología y Transducción de Señales, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Viviana Blank
- Laboratorio de Oncología y Transducción de Señales, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Leonor Roguin
- Laboratorio de Oncología y Transducción de Señales, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Martín J Riveira
- Instituto de Química Rosario, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario-CONICET, Rosario, Argentina
| |
Collapse
|
|
30
|
Mitchell RJ, Delaney GP, Arnolda G, Liauw W, Lystad RP, Braithwaite J. Three-year hospital service use trajectories of people diagnosed with cancer: A retrospective cohort study. Cancer Epidemiol 2024; 93:102676. [PMID: 39303658 DOI: 10.1016/j.canep.2024.102676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 08/27/2024] [Accepted: 09/14/2024] [Indexed: 09/22/2024]
Abstract
BACKGROUND Information regarding hospital service use by people newly diagnosed with cancer can inform patterns of healthcare utilisation and resource demands. This study aims to identify characteristics of group-based trajectories of hospital service use three years after an individual was diagnosed with cancer; and determine factors predictive of trajectory group membership. METHOD A group-based trajectory analysis of hospital service use of people aged ≥30 years who had a new diagnosis of cancer during 2018 in New South Wales, Australia was conducted. Linked cancer registry, hospital and mortality data were examined for a three-year period after diagnosis. Group-based trajectory models were derived based on number of hospital admissions. Multinominal logistic regression examined predictors of trajectory group membership. RESULTS Of the 44,577 new cancer diagnosis patients, 29,085 (65.2 %) were hospitalised at least once since their cancer diagnosis. Four distinct trajectory groups of hospital users were identified: Low (68.4 %), Very-Low (25.1 %), Moderate-Chronic (2.2 %), and Early-High (4.2 %). Key predictors of trajectory group membership were age group, cancer type, degree of cancer spread, prior history of cancer, receiving chemotherapy, and presence of comorbidities, including renal disease, moderate/serious liver disease, or anxiety. CONCLUSIONS Comorbidities should be considered in cancer treatment and management decision making. Caring for people diagnosed with cancer with multimorbidity requires multidisciplinary shared care.
Collapse
Affiliation(s)
- Rebecca J Mitchell
- Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
| | - Geoffrey P Delaney
- Maridulu Budyari Gumal - Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), University of New South Wales, Sydney, Australia; Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia; Collaboration for Cancer Outcomes Research and Evaluation, South-Western Sydney Clinical School, University of New South Wales, Sydney, Australia; University of New South Wales School of Clinical Medicine, Sydney, Australia
| | - Gaston Arnolda
- Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
| | - Winston Liauw
- University of New South Wales School of Clinical Medicine, Sydney, Australia; Cancer Care Centre, St George Hospital, Kogarah, Australia
| | - Reidar P Lystad
- Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
| | - Jeffrey Braithwaite
- Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
| |
Collapse
|
|
31
|
Ryan D, Bou Dargham T, Ikramuddin S, Shekhar S, Sengupta S, Feng W. Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke. Cancers (Basel) 2024; 16:4016. [PMID: 39682202 DOI: 10.3390/cancers16234016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 11/25/2024] [Accepted: 11/26/2024] [Indexed: 12/18/2024] Open
Abstract
Cancer and stroke are leading causes of global disability and mortality. With improvements in cancer-associated mortality and advancements in treatment of active malignancy, it is more common to encounter patients with ischemic stroke and active malignancy. Evidence suggests that cancer-associated ischemic stroke is a unique subtype of stroke; however, there is limited guidance when considering diagnostic workup, secondary prevention, rehabilitation, and future directions within this population. In this narrative review, we aim to describe the epidemiology, pathophysiological mechanisms, management, and future directions regarding understanding of cancer-associated ischemic stroke.
Collapse
Affiliation(s)
- Dylan Ryan
- Department of Neurology, Duke University School of Medicine, Durham, NC 27704, USA
| | - Tarek Bou Dargham
- Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
| | - Salman Ikramuddin
- Department of Neurology, University of Texas Health Sciences Houston, Houston, TX 77030, USA
| | - Shashank Shekhar
- Department of Neurology, Duke University School of Medicine, Durham, NC 27704, USA
| | - Soma Sengupta
- Department of Neurology, University of North Carolina, Chapel Hill, NC 27599, USA
| | - Wuwei Feng
- Department of Neurology, Duke University School of Medicine, Durham, NC 27704, USA
| |
Collapse
|
|
32
|
Ajikumar A, Lei KF. Microfluidic Technologies in Advancing Cancer Research. MICROMACHINES 2024; 15:1444. [PMID: 39770196 PMCID: PMC11677295 DOI: 10.3390/mi15121444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 11/25/2024] [Accepted: 11/27/2024] [Indexed: 01/11/2025]
Abstract
This review explores the significant role of microfluidic technologies in advancing cancer research, focusing on the below key areas: droplet-based microfluidics, organ-on-chip systems, paper-based microfluidics, electrokinetic chips, and microfluidic chips for the study of immune response. Droplet-based microfluidics allows precise manipulation of cells and three-dimensional microtissues, enabling high-throughput experiments that reveal insights into cancer cell migration, invasion, and drug resistance. Organ-on-chip systems replicate human organs to assess drug efficacy and toxicity, particularly in the liver, heart, kidney, gut, lung, and brain. Paper-based microfluidics offers an alternative approach to accomplish rapid diagnostics and cell- and tissue-based bioassays. Electrokinetic microfluidic chips offer precise control over cell positioning and behavior, facilitating drug screening and cellular studies. Immune response studies leverage real-time observation of interactions between immune and cancer cells, supporting the development of immunotherapies. These microfluidic advances are paving the way for personalized cancer treatments while addressing challenges of scalability, cost, and clinical integration.
Collapse
Affiliation(s)
- Arjun Ajikumar
- Department of Biomedical Engineering, Chang Gung University, Taoyuan 33302, Taiwan;
| | - Kin Fong Lei
- Department of Biomedical Engineering, Chang Gung University, Taoyuan 33302, Taiwan;
- Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan
- Department of Electrical & Electronic Engineering, Yonsei University, Seoul 03722, Republic of Korea
| |
Collapse
|
|
33
|
Van Cauwenbergh O, Willers N, Vandenbroucke T, Neven P, Han S. Sexuality after breast cancer treatment: A physician's survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol 2024; 302:317-324. [PMID: 39362129 DOI: 10.1016/j.ejogrb.2024.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Revised: 09/11/2024] [Accepted: 09/13/2024] [Indexed: 10/05/2024]
Abstract
BACKGROUND Side effects of breast cancer treatment (BCT) impact patients' general and sexual wellbeing. Sexuality related complaints are reported by 70% of breast cancer survivors mainly due to the genitourinary syndrome of menopause (GSM). In clinical care, sexual side effects are often un(der)detected because physicians as well as patients experience barriers to discuss sexuality-related issues. MATERIALS AND METHODS We composed an online survey ourselves using known definitions about sexuality and menopause and known factors for not discussing sexuality. We used multiple-choice questions with a Likert scale to optimize interpretation of the statements. 64 practitioners completed the survey. With this online survey, we examined physicians' knowledge of -and attitude towards- sexual wellbeing and detection and treatment of GSM in breast cancer survivors (BCS). RESULTS Vaginal dryness and dyspareunia were the symptoms most associated with menopause (n = 63/64 (98 %) and n = 56/64 (87 %)) and sexuality (n = 63/64 (98 %) and n = 61/64 (95 %)). These 2 complaints were also the most discussed symptoms of menopause (vaginal dryness n = 51/64 (80 %) and dyspareunia n = 45/64 (70 %)). The main reason to not discuss these issues were absence of reporting GSM (n = 40/64 (62 %)) and absence of a direct cause to discuss GSM (n = 35/64 (55 %). 64 % (n = 41/64) of practitioners don't feel sufficiently educated to discuss and treat GSM. They proposed vaginal estrogens to treat GSM as first or second line respectively in 12 % (n = 8/64) and 46 % (n = 30/64) of symptomatic BCS. DISCUSSION Although sexuality related complaints are common in BCS, 64% of all participating physicians feel they are not adequately trained to handle them. More attention towards training of physicians is needed to discuss GSM related complaints also when they are not spontaneously reported by a patient and with clear guidance towards the medical treatment of GSM in BCS.
Collapse
Affiliation(s)
| | - Nynke Willers
- University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium.
| | | | - Patrick Neven
- University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium.
| | - Sileny Han
- University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium.
| |
Collapse
|
|
34
|
Barbosa-Azevedo M, Dias-Carvalho A, Carvalho F, Costa VM. Chemotherapy-induced cognitive impairment and glia: A new take on chemobrain? Toxicol Appl Pharmacol 2024; 492:117085. [PMID: 39236990 DOI: 10.1016/j.taap.2024.117085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 07/03/2024] [Accepted: 09/02/2024] [Indexed: 09/07/2024]
Abstract
The significant rise in cancer survivorship stands out as one of the most notable achievements of modern science. However, this comes with a significant burden, as cancer treatment is not without adverse effects. Lately, there has been a growing focus on cognitive dysfunction associated with cancer treatment, often referred to as 'chemobrain'. It significantly impacts the quality of life for cancer survivors. The underlying mechanisms studied so far usually focus on neurons, while other cells of the central nervous system are often overlooked. This review seeks to place the hypothesis that glial cells may play a role in the development of chemotherapy-induced cognitive dysfunction. It summarizes the primary mechanisms proposed to date while underscoring the existing gaps in this research field. Inflammation and release of pro-inflammatory mediators by M1 microglia and A1 astrocytes are the most prevalent findings after chemotherapy. However, activation of A1 astrocytes by some chemotherapeutic agents may contribute to neuronal degeneration, alterations in synaptic branches, as well as glutamate excitotoxicity, which can contribute to cognitive impairment. Furthermore, the reduction in the number of oligodendrocytes after chemotherapy may also impact the myelin sheath, contributing to 'chemobrain'. Furthermore, some chemotherapeutic drugs activate M1 microglia, which is associated with decreased neuroplasticity and, possibly, cognitive impairment. In conclusion, data regarding the effects of chemotherapy on glial cells are scarce, and it is essential to understand how these cells are affected after cancer treatment to enable reliable therapeutic or preventive actions on cancer-treated patients.
Collapse
Affiliation(s)
- Maria Barbosa-Azevedo
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Ana Dias-Carvalho
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Félix Carvalho
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Vera Marisa Costa
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO - Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
| |
Collapse
|
|
35
|
Belau MH. Material and social deprivation associated with public health actual causes of death among older people in Europe: longitudinal and multilevel results from the Survey of Health, Ageing and Retirement in Europe (SHARE). Front Public Health 2024; 12:1469203. [PMID: 39534740 PMCID: PMC11556392 DOI: 10.3389/fpubh.2024.1469203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2024] [Accepted: 10/14/2024] [Indexed: 11/16/2024] Open
Abstract
Background Adverse socioeconomic conditions at the individual and regional levels are associated with an increased risk of mortality. However, few studies have examined this relationship using multilevel analysis and, if so, only within a single country. This study aimed to examine this relationship using data from several European countries. Methods Individual-level data were obtained from Waves 5 to 9 of the Survey of Health, Ageing and Retirement in Europe, while regional-level data were obtained from the Luxembourg Income Study Database. Cox regression analysis with gamma-shared frailty and a random intercept for country of residence was used to examine the association between individual mortality from all causes, cancer, heart attack, and stroke and measures of socioeconomic deprivation at the individual level, including material and social deprivation indices, and at the area level, including the Gini index. Results The risk of mortality from all causes was increased for respondents with material deprivation (hazard ratio (HR) = 1.77, 95% CI = [1.60, 1.96]) and social deprivation (HR = 7.63, 95% CI = [6.42, 9.07]) compared with those without. A similar association was observed between individual deprivation and the risk of mortality from cancer, heart attack, or stroke. Regional deprivation had a modest contextual effect on the individual risk of death from all causes and cancer. However, when individual-level deprivation was included in the models, no contextual effects were found. Conclusion The results indicate that individual socioeconomic conditions significantly predict causes of death in older European adults, with those with material deprivation and social deprivation having a higher risk of death from all causes, including cancer, heart attack, and stroke, while the Gini index has a minimal effect, although the Gini index reflects regional disparities across Europe.
Collapse
Affiliation(s)
- Matthias Hans Belau
- University Medical Centre Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany
| |
Collapse
|
|
36
|
Dong Y, Zhou X, Ding Y, Luo Y, Zhao H. Advances in tumor microenvironment: Applications and challenges of 3D bioprinting. Biochem Biophys Res Commun 2024; 730:150339. [PMID: 39032359 DOI: 10.1016/j.bbrc.2024.150339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 06/27/2024] [Accepted: 07/01/2024] [Indexed: 07/23/2024]
Abstract
The tumor microenvironment (TME) assumes a pivotal role in the treatment of oncological diseases, given its intricate interplay of diverse cellular components and extracellular matrices. This dynamic ecosystem poses a serious challenge to traditional research methods in many ways, such as high research costs, inefficient translation, poor reproducibility, and low modeling success rates. These challenges require the search for more suitable research methods to accurately model the TME, and the emergence of 3D bioprinting technology is transformative and an important complement to these traditional methods to precisely control the distribution of cells, biomolecules, and matrix scaffolds within the TME. Leveraging digital design, the technology enables personalized studies with high precision, providing essential experimental flexibility. Serving as a critical bridge between in vitro and in vivo studies, 3D bioprinting facilitates the realistic 3D culturing of cancer cells. This comprehensive article delves into cutting-edge developments in 3D bioprinting, encompassing diverse methodologies, biomaterial choices, and various 3D tumor models. Exploration of current challenges, including limited biomaterial options, printing accuracy constraints, low reproducibility, and ethical considerations, contributes to a nuanced understanding. Despite these challenges, the technology holds immense potential for simulating tumor tissues, propelling personalized medicine, and constructing high-resolution organ models, marking a transformative trajectory in oncological research.
Collapse
Affiliation(s)
- Yingying Dong
- The First School of Climical Medicine of Zhejiang Chinese Medical University, Hangzhou, 310053, China.
| | - Xue Zhou
- School of Mechanical Engineering, Zhejiang University, Hangzhou, 310058, China; State Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, China.
| | - Yunyi Ding
- Department of Emergency Medicine, The Second Affiliated Hospital of Zhejiang University, School, Hangzhou, 310009, China.
| | - Yichen Luo
- School of Mechanical Engineering, Zhejiang University, Hangzhou, 310058, China; State Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, China.
| | - Hong Zhao
- The First School of Climical Medicine of Zhejiang Chinese Medical University, Hangzhou, 310053, China; Department of Breast Surgery, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310060, China.
| |
Collapse
|
|
37
|
Nickerson JL, Cyr C, Arseneau RJ, Lee SN, Condon-Oldreive S, Zogopoulos G, Roberts K, Kim CA, Ng SSW, Haider M, Villalba E, Stephenson L, Tsang E, Johnston B, Gala-Lopez B, Cooper V, Hannon B, Gangloff A, Gill S, Servidio-Italiano F, Ramjeesingh R. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Curr Oncol 2024; 31:6191-6204. [PMID: 39451765 PMCID: PMC11506161 DOI: 10.3390/curroncol31100461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Revised: 10/02/2024] [Accepted: 10/14/2024] [Indexed: 10/26/2024] Open
Abstract
Pancreatic cancer is a complex malignancy associated with poor prognosis and high symptom burden. Optimal patient care relies on the integration of various sectors in the healthcare field as well as innovation through research. The Canadian National Pancreas Conference (NPC) was co-organized and hosted by Craig's Cause Pancreatic Cancer Society and The Royal College of Physicians and Surgeons in November 2023 in Montreal, Canada. The conference sought to bridge the gap between Canadian healthcare providers and researchers who share the common goal of improving the prognosis, quality of life, and survival for patients with pancreatic cancer. The accredited event featured discussion topics including diagnosis and screening, value-based and palliative care, pancreatic enzyme replacement therapy, cancer-reducing treatment, and an overview of the current management landscape. The present article reviews the NPC sessions and discusses the presented content with respect to the current literature.
Collapse
Affiliation(s)
- Jessica L. Nickerson
- Allumiqs Corporation, Halifax, NS B3H 0A8, Canada;
- Craig’s Cause Pancreatic Cancer Society, Halifax, NS B3K 5M3, Canada; (C.C.); (R.J.A.); (S.N.L.); (S.C.-O.)
| | - Chloe Cyr
- Craig’s Cause Pancreatic Cancer Society, Halifax, NS B3K 5M3, Canada; (C.C.); (R.J.A.); (S.N.L.); (S.C.-O.)
- Department of Kinesiology, Dalhousie University, Halifax, NS B3H 4R2, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 0A2, Canada
| | - Riley J. Arseneau
- Craig’s Cause Pancreatic Cancer Society, Halifax, NS B3K 5M3, Canada; (C.C.); (R.J.A.); (S.N.L.); (S.C.-O.)
- Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 0A2, Canada
- Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada
| | - Stacey N. Lee
- Craig’s Cause Pancreatic Cancer Society, Halifax, NS B3K 5M3, Canada; (C.C.); (R.J.A.); (S.N.L.); (S.C.-O.)
- Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 0A2, Canada
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada;
| | - Stefanie Condon-Oldreive
- Craig’s Cause Pancreatic Cancer Society, Halifax, NS B3K 5M3, Canada; (C.C.); (R.J.A.); (S.N.L.); (S.C.-O.)
| | | | - Keith Roberts
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK;
| | - Christina A. Kim
- Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada;
| | - Sylvia S. W. Ng
- Section of Medical Oncology and Hematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W2, Canada;
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
| | - Masoom Haider
- Joint Department of Medical Imaging, Sinai Health System, Toronto, ON M5G 1X6, Canada;
| | - Eva Villalba
- Quebec Cancer Coalition, Saint-Lambert, QC J4P 2J7, Canada;
| | | | - Erica Tsang
- Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada;
| | - Brent Johnston
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada;
| | - Boris Gala-Lopez
- Department of Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada;
| | - Valerie Cooper
- South East Local Health Integration Network, Belleville, ON K8N 5K3, Canada;
| | - Breffni Hannon
- Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada;
| | - Anne Gangloff
- Faculty of Medicine, Laval University, Quebec, QC G1V 0A6, Canada;
| | | | | | - Ravi Ramjeesingh
- Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada
| |
Collapse
|
|
38
|
Ghajar A, Khant KM, Sargeant MM, Bandarupalli T, Philips B, Assis FR, Catanzaro JN, Nekkanti R, Sears SF, Shantha G. All-cause mortality due to conduction abnormalities in the United States: Sex, racial, and geographic variations from 1999 to 2022. Heart Rhythm 2024:S1547-5271(24)03299-5. [PMID: 39260663 DOI: 10.1016/j.hrthm.2024.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Revised: 08/20/2024] [Accepted: 09/04/2024] [Indexed: 09/13/2024]
Abstract
BACKGROUND Mortality related to conduction abnormalities in the United States (US) population is not well documented. Population-based stratification approaches can improve public health policies and targeted strategies. OBJECTIVE The purpose of this study was to evaluate all-cause mortality related to conduction abnormalities in the US population METHODS: The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was used to calculate the age-adjusted mortality rate (AAMR) per 100,000 individuals older than 35 years related to conduction abnormalities between 1999 and 2022. RESULTS A total of 207,861 deaths were attributed to conduction abnormalities throughout the study period ,with 56,186 of these deaths occurring between 2020 and 2022. All-cause mortality related to conduction abnormalities has increased during the past decade with an exponential growth in 2020-2021 (coronavirus disease 2019 era; annual percent change of 16.6% per year). Although the mortality rates decreased in 2022, they remained elevated compared to 2019-2020. Throughout the past 2 decades, males consistently exhibited higher mortality rates than females, with the rate in 2022 being 1.5 times higher (AAMR 11.4 vs 7.0 per 100,000). Non-Hispanic Black patients experienced a significantly higher mortality rate compared to non-Hispanic White individuals in the study period (AAMR 13.7 vs 8.6 per 100,000 in 2022). In the past 2 decades, mortality has been persistently higher in rural and small- to medium-sized metropolitan areas than in large metropolitan urban areas. CONCLUSION Mortality rates related to conduction abnormalities have increased over the past decade, and persistent disparities have been observed. These data suggest that continued innovative outreach approaches and engagement with underrepresented populations remain essential.
Collapse
Affiliation(s)
- Alireza Ghajar
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - Kyaw M Khant
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - Maeve M Sargeant
- Department of Psychology, East Carolina University, Greenville, North Carolina
| | - Tharun Bandarupalli
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - Binu Philips
- Division of Cardiology, Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts; Harvard Medical School, Boston, Massachusetts
| | - Fabrizio R Assis
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - John N Catanzaro
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - Rajasekhar Nekkanti
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina
| | - Samuel F Sears
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina; Department of Psychology, East Carolina University, Greenville, North Carolina
| | - Ghanshyam Shantha
- Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina.
| |
Collapse
|
|
39
|
Zhou X, Nie M, Xin X, Hua T, Zhang J, Shi R, Dong K, Shu W, Yan B, Wang H. RAB17 promotes endometrial cancer progression by inhibiting TFRC-dependent ferroptosis. Cell Death Dis 2024; 15:655. [PMID: 39242574 PMCID: PMC11379720 DOI: 10.1038/s41419-024-07013-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 08/13/2024] [Accepted: 08/19/2024] [Indexed: 09/09/2024]
Abstract
Studies have indicated that RAB17 expression levels are associated with tumor malignancy, and RAB17 is more highly expressed in endometrial cancer (EC) tissues than in peritumoral tissues. However, the roles and potential mechanisms of RAB17 in EC remain undefined. The present study confirmed that the expression of RAB17 facilitates EC progression by suppressing cellular ferroptosis-like alterations. Mechanistically, RAB17 attenuated ferroptosis in EC cells by inhibiting transferrin receptor (TFRC) protein expression in a ubiquitin proteasome-dependent manner. Because EC is a blood-deprived tumor with a poor energy supply, the relationship between RAB17 and hypoglycemia was investigated. RAB17 expression was increased in EC cells incubated in low-glucose medium. Moreover, low-glucose medium limited EC cell ferroptosis and promoted EC progression through the RAB17-TFRC axis. The in vitro results were corroborated by in vivo studies and clinical data. Overall, the present study revealed that increased RAB17 promotes the survival of EC cells during glucose deprivation by inhibiting the onset of TFRC-dependent ferroptosis.
Collapse
Affiliation(s)
- Xing Zhou
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Miaomiao Nie
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Xiaoyan Xin
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Teng Hua
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Jun Zhang
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Rui Shi
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Kejun Dong
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Wan Shu
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China
| | - Bei Yan
- Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China.
| | - Hongbo Wang
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, P. R. China.
| |
Collapse
|
|
40
|
Wang J, Guo T, Zhang X, Guo J, Meng X, Yan S, Wang Y, Xiao Y, Xu W, Wei X, Ding K, Zhang J, Mi Y, Wu S, Chen J, Huang Y, Ren S, Hou J. Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer. Transl Oncol 2024; 47:102049. [PMID: 38964031 PMCID: PMC11283080 DOI: 10.1016/j.tranon.2024.102049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 06/06/2024] [Accepted: 07/01/2024] [Indexed: 07/06/2024] Open
Abstract
BACKGROUND Nuclear cap-binding protein 2 (NCBP2), as the component of the cap-binding complex, participates in a number of biological processes, including pre-mRNA splicing, transcript export, translation regulation and other gene expression steps. However, the role of NCBP2 on the tumor cells and immune microenvironment remains unclear. To systematically analyze and validate functions of NCBP2, we performed a pan-cancer analysis using multiple approaches. METHODS The data in this study were derived from sequencing, mutation, and methylation data in the TCGA cohort, normal sample sequencing data in the GTEx project, and cell line expression profile data in the CCLE database. RESULTS Survival analyses including the Cox proportional-hazards model and log-rank test revealed the poor prognostic role of NCBP2 in multiple tumors. We further validated the oncogenic ability of NCBP2 in prostate cancer cell lines, organoids and tumor-bearing mice. A negative correlation was observed between NCBP2 expression and immune score by the ESTIMATE algorithm. Simultaneously, the NCBP2-induced immunosuppressive microenvironment might be related to the decline in CD8+T cells and the increase in regulatory T cells and neutrophils, examined by flow cytometry experiments for NCBP2 overexpressed tumor-bearing mice. CONCLUSION This research offered strong proof supporting NCBP2 as the prognostic marker and the therapeutic target in the future.
Collapse
Affiliation(s)
- Jian Wang
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China; Department of Urology, Shanghai Changzheng Hospital, Shanghai, China; Department of Urology, Shanghai Changhai Hospital, Shanghai, China; Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China
| | - Tao Guo
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaomin Zhang
- Department of Urology, Shanghai Changhai Hospital, Shanghai, China
| | - Jiacheng Guo
- CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
| | - Xiangyu Meng
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing China
| | - Shi Yan
- Department of Urology, Shanghai Changhai Hospital, Shanghai, China
| | - Ye Wang
- Department of Urology, Shanghai Changzheng Hospital, Shanghai, China
| | - Yutian Xiao
- Department of Urology, Shanghai Changhai Hospital, Shanghai, China
| | - Weidong Xu
- Department of Urology, Shanghai Changzheng Hospital, Shanghai, China
| | - Xuedong Wei
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Keke Ding
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jun Zhang
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yuanyuan Mi
- Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China
| | - Sheng Wu
- Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China
| | - Jie Chen
- Department of Urology, Shanghai Changzheng Hospital, Shanghai, China.
| | - Yuhua Huang
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
| | - Shancheng Ren
- Department of Urology, Shanghai Changzheng Hospital, Shanghai, China.
| | - Jianquan Hou
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
| |
Collapse
|
|
41
|
McGill KC, Baal JD, Bucknor MD. Update on musculoskeletal applications of magnetic resonance-guided focused ultrasound. Skeletal Radiol 2024; 53:1869-1877. [PMID: 38363419 PMCID: PMC11303439 DOI: 10.1007/s00256-024-04620-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Revised: 02/02/2024] [Accepted: 02/08/2024] [Indexed: 02/17/2024]
Abstract
Magnetic resonance-guided focused ultrasound (MRgFUS) is a noninvasive, incisionless, radiation-free technology used to ablate tissue deep within the body. This technique has gained increased popularity following FDA approval for treatment of pain related to bone metastases and limited approval for treatment of osteoid osteoma. MRgFUS delivers superior visualization of soft tissue targets in unlimited imaging planes and precision in targeting and delivery of thermal dose which is all provided during real-time monitoring using MR thermometry. This paper provides an overview of the common musculoskeletal applications of MRgFUS along with updates on clinical outcomes and discussion of future applications.
Collapse
Affiliation(s)
- Kevin C McGill
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, Suite M391, San Francisco, CA, 94143, USA.
| | - Joe D Baal
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, Suite M391, San Francisco, CA, 94143, USA
| | - Matthew D Bucknor
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave, Suite M391, San Francisco, CA, 94143, USA
| |
Collapse
|
|
42
|
Feng Q, Liu Q, Liu Z, Xu J, Yang Y, Zhu Y, Lu G, Xu G, Wu D, Wang F, Liu B, Wang W, Ding X. USP9X inhibits metastasis in pulmonary sarcomatoid carcinoma by regulating epithelial-mesenchymal transition, angiogenesis and immune infiltration. Transl Oncol 2024; 47:101950. [PMID: 38964032 PMCID: PMC11283126 DOI: 10.1016/j.tranon.2024.101950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 03/06/2024] [Accepted: 03/26/2024] [Indexed: 07/06/2024] Open
Abstract
BACKGROUND Pulmonary sarcomatoid carcinoma (PSC) is a highly invasive pulmonary malignancy with an extremely poor prognosis. The results of previous studies suggest that ubiquitin-specific peptidase 9X (USP9X) contributes to the progression of numerous types of cancer. Nevertheless, there is little knowledge about the molecular mechanisms and functions of USP9X in the metastasis of PSC. METHODS Immunohistochemistry and western blotting were used to detect USP9X expression levels in PSC tissues and cells. Wound healing, transwell, enzyme-linked immunosorbent assay (ELISA), tube formation, and aortic ring assays were used to examine the function and mechanism of USP9X in the metastasis of PSC. RESULTS Expression of USP9X was markedly decreased and significantly correlated with metastasis and prognosis of patients with PSC. Then we revealed that USP9X protein levels were negatively associated with the levels of epithelial-mesenchymal transition (EMT) markers and the migration of PSC cells. It was confirmed that USP9X in PSC cells reduced VEGF secretion and inhibited tubule formation of human umbilical vein endothelial cells (HUVEC) in vitro. USP9X was detected to downregulate MMP9. Meanwhile, MMP9 was positively related to EMT, angiogenesis and was negatively related to immune infiltration in the public databases. USP9X was significantly negatively associated with the expression of MMP9, EMT markers, CD31, and positively associated with CD4, and CD8 in PSC tissues. CONCLUSION The present study reveals the vital role of USP9X in regulating EMT, angiogenesis and immune infiltration and inhibiting metastasis of PSC via downregulating MMP9, which provides a new effective therapeutic target for PSC.
Collapse
Affiliation(s)
- Qin Feng
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Qian Liu
- Department of Pathology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Zi Liu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Jianyu Xu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Yang Yang
- Department of Pathology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
| | - Ying Zhu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Guangxian Lu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Guangjuan Xu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Dan Wu
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Feng Wang
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China
| | - Biao Liu
- Department of Pathology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
| | - Wenjuan Wang
- Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
| | - Xinyuan Ding
- Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Minicipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.
| |
Collapse
|
|
43
|
Lou X, Wang Y, Deng Y, Yang J, Xu D, Wang M, Lin Y. Prognostic and immunological roles of RSPO1 in pan-cancer and its correlation with LUAD proliferation and metastasis. Am J Cancer Res 2024; 14:3800-3815. [PMID: 39267661 PMCID: PMC11387876 DOI: 10.62347/dlvs6991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2024] [Accepted: 08/06/2024] [Indexed: 09/15/2024] Open
Abstract
Aberrant RSPO1 expression is implicated in tumor progression across various cancers and correlates with anti-cancer immune cell characteristics. However, the specific role of R-spondin 1 (RSPO1) in lung adenocarcinoma (LUAD) remains unclear. In this study, we utilized data from The Cancer Genome Atlas (TCGA) to assess RSPO1 expression across 33 tumor types. Kaplan-Meier (K-M) analysis revealed the prognostic significance of RSPO1 in various cancers. Using statistical software R, we examined RSPO1's associations with immune cell infiltration, methylation, mutation, and competing endogenous RNA (ceRNA) networks. Exploration via the Tumor Immune Single Cell Hub (TISCH) database uncovered RSPO1's link to the tumor microenvironment (TME) and identified potential small molecule drug targets. We further investigated RSPO1's impact on LUAD cell proliferation, metastasis, and the Wnt pathway in vitro. Our findings highlight RSPO1's role in cancer progression and suggest its potential as both a prognostic marker and therapeutic target in LUAD, implicating the modulation of the Wnt pathway.
Collapse
Affiliation(s)
- Xinqi Lou
- Institute of Clinical Medicine Research, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Yuanyuan Wang
- Department of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Yanjun Deng
- Department of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Jiao Yang
- Institute of Clinical Medicine Research, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Duo Xu
- Department of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Mingdeng Wang
- Department of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| | - Yuansheng Lin
- Department of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University Suzhou 215000, Jiangsu, China
| |
Collapse
|
|
44
|
Liu Y, Li H, Shen X, Liu Y, Zhong X, Zhong J, Cao R. PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis. Am J Cancer Res 2024; 14:3711-3732. [PMID: 39267673 PMCID: PMC11387850 DOI: 10.62347/tyll7952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 08/07/2024] [Indexed: 09/15/2024] Open
Abstract
Protein L-isoaspartyl (D-aspartyl) methyltransferase (PIMT, gene name PCMT1) is an enzyme that repairs proteins with altered aspartate residues by methylation, restoring their normal structure and function. This study conducted a comprehensive analysis of PCMT1 in pan-cancer. The Cancer Genome Atlas, Human Protein Atlas website, and the Genotype-Tissue Expression were utilized in analysis of PCMT1 expression. We examined the association between PCMT1 expression and various factors, including gene modifications, DNA methylation, immune cell infiltration, immunological checkpoints, drug susceptibility, tumor mutation burden (TMB), and microsatellite instability (MSI). Enrichment analyses determined the potential biological roles and pathways involving PCMT1. Our focus then shifted to the role of PCMT1 in breast invasive carcinoma (BRCA). We found that PCMT1 expression was aberrant in many tumors and significantly influenced the prognosis across several cancer types. Gene alterations in PCMT1 predominantly involved deep deletions and amplifications. A negative correlation was observed between DNA methylation and PCMT1 expression across all studied cancer types except thyroid carcinoma PCMT1 exhibited positive correlations with common lymphoid progenitor and CD4(+) T helper 2 cells, whereas it was inversely correlated with central and effector memory T cells, memory CD8(+) T cells, and CD4(+) T helper 1 cells. In many cancer types, PCMT1 expression closely correlated with immunological checkpoint inhibitors, TMB, and MSI. It was also significantly linked to pathways involved in epithelial-mesenchymal transition (EMT), highlighting its role in cancer metastasis. PCMT1 emerged as a significant predictor of breast cancer progression. In vitro experiments demonstrated that reducing PCMT1 expression decreased BRCA cell migration and invasiveness. Additionally, animal studies confirmed that inhibition of PCMT1 slowed tumor growth.
Collapse
Affiliation(s)
- Yiqi Liu
- The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421001, Hunan, China
| | - Haobing Li
- Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
- Department of Medical Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
| | - Xiangyu Shen
- Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University Changsha 410000, Hunan, China
| | - Ying Liu
- Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
- Department of Medical Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
| | - Xiaoxiao Zhong
- Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University Changsha 410000, Hunan, China
- Department of General Surgery, Third Xiangya Hospital, Central South University Changsha 410000, Hunan, China
| | - Jing Zhong
- Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
- Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
| | - Renxian Cao
- Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
- Institute of Cancer Research, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China
| |
Collapse
|
|
45
|
Kim C, Oh S, Im H, Gim J. Unveiling Bladder Cancer Prognostic Insights by Integrating Patient-Matched Sample and CpG Methylation Analysis. MEDICINA (KAUNAS, LITHUANIA) 2024; 60:1175. [PMID: 39064604 PMCID: PMC11279046 DOI: 10.3390/medicina60071175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Revised: 07/07/2024] [Accepted: 07/17/2024] [Indexed: 07/28/2024]
Abstract
Bladder cancer prognosis remains a pressing clinical challenge, necessitating the identification of novel biomarkers for precise survival prediction and improved quality of life outcomes. This study proposes a comprehensive strategy to uncover key prognostic biomarkers in bladder cancer using DNA methylation analysis and extreme survival pattern observations in matched pairs of cancer and adjacent normal cells. Unlike traditional approaches that overlook cancer heterogeneity by analyzing entire samples, our methodology leverages patient-matched samples to account for this variability. Specifically, DNA methylation profiles from adjacent normal bladder tissue and bladder cancer tissue collected from the same individuals were analyzed to pinpoint critical methylation changes specific to cancer cells while mitigating confounding effects from individual genetic differences. Utilizing differential threshold settings for methylation levels within cancer-associated pathways enabled the identification of biomarkers that significantly impact patient survival. Our analysis identified distinct survival patterns associated with specific CpG sites, underscoring these sites' pivotal roles in bladder cancer outcomes. By hypothesizing and testing the influence of methylation levels on survival, we pinpointed CpG biomarkers that profoundly affect the prognosis. Notably, CpG markers, such as cg16269144 (PRKCZ), cg16624272 (PTK2), cg11304234, and cg26534425 (IL18), exhibited critical methylation thresholds that correlate with patient mortality. This study emphasizes the importance of tailored approaches to enhancing prognostic accuracy and refining therapeutic strategies for bladder cancer patients. The identified biomarkers pave the way for personalized prognostication and targeted interventions, promising advancements in bladder cancer management and patient care.
Collapse
Affiliation(s)
- Chanbyeol Kim
- Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea; (C.K.); (S.O.); (H.I.)
- AI Convergence College, Chosun University, Gwangju 61452, Republic of Korea
| | - Sangwon Oh
- Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea; (C.K.); (S.O.); (H.I.)
- AI Convergence College, Chosun University, Gwangju 61452, Republic of Korea
| | - Hamin Im
- Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea; (C.K.); (S.O.); (H.I.)
- AI Convergence College, Chosun University, Gwangju 61452, Republic of Korea
| | - Jungsoo Gim
- Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea; (C.K.); (S.O.); (H.I.)
- AI Convergence College, Chosun University, Gwangju 61452, Republic of Korea
- BK FOUR Department of Integrative Biological Science, Chosun University, Gwangju 61452, Republic of Korea
- Well-Ageing Medicare Institute, Chosun University, Gwangju 61452, Republic of Korea
- Asian Dementia Research Initiative, Chosun University, Gwangju 61452, Republic of Korea
| |
Collapse
|
|
46
|
Bleumer T, Abel J, Böhmerle W, Schröder S, Yap SA, Schaeper NDE, Hummel T, Stintzing S, Stephan LU, Pelzer U. Smell and Taste Alterations in Patients Receiving Curative or Palliative Chemotherapy-The CONKO 021-ChemTox Trial. Cancers (Basel) 2024; 16:2495. [PMID: 39061135 PMCID: PMC11274726 DOI: 10.3390/cancers16142495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Revised: 07/04/2024] [Accepted: 07/08/2024] [Indexed: 07/28/2024] Open
Abstract
Previous data regarding chemotherapy-induced olfactory and gustatory dysfunction (CIOGD) are heterogeneous due to inconsistent study designs and small numbers of patients. To provide consistent, reliable data, we conducted a cohort study using standardized testing. Patients diagnosed with lymphoma, leukemia, or gastrointestinal malignancies were examined up to five times (T1 to T5), beginning prior to chemotherapy. We examined patients receiving temporary treatment up to 12 months post-therapy. Clinical assessment included extensive questionnaires, psychophysical tests of olfactory and gustatory function, and measurement of peripheral neuropathy. Statistical analysis included non-parametric tests to evaluate the longitudinal development of CIOGD. Our data (n = 108) showed a significant decline in olfactory and gustatory testing during chemotherapy (p-values < 0.001). CIOGD appeared stronger among patients above 60 years, while sex did not matter significantly. However, we identified distinct associations between CIOGD and reported anorexia as well as with higher neuropathy scores. Self-assessment appeared less sensitive to chemosensory dysfunction than psychophysical testing. Post-therapy, olfactory and gustatory function regenerated, though baseline levels were not attained within 6 to 12 months. In conclusion, our data highlight the wide prevalence and slow recovery of CIOGD. Understanding CIOGD as a potential neurotoxic effect may disclose new therapeutic prospects.
Collapse
Affiliation(s)
- Tobias Bleumer
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Janine Abel
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Wolfgang Böhmerle
- Department of Neurology and Experimental Neurology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany;
| | - Sebastian Schröder
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Soo Ann Yap
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Nigel Dross Engelbert Schaeper
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Thomas Hummel
- Smell & Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, 01307 Dresden, Germany
| | - Sebastian Stintzing
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| | - Lars Uwe Stephan
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
- Department of Internal Medicine, Bundeswehrkrankenhaus Berlin, 10115 Berlin, Germany
| | - Uwe Pelzer
- Department of Hematology, Oncology and Tumor Immunology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany; (T.B.); (J.A.); (S.S.); (S.A.Y.); (N.D.E.S.); (S.S.); (L.U.S.)
| |
Collapse
|
|
47
|
Tsutsumi WD, Rattanasuwan A, Aryasit O. Clinical features and treatment outcomes of intraocular and ocular adnexal metastasis. Sci Rep 2024; 14:15258. [PMID: 38956127 PMCID: PMC11219807 DOI: 10.1038/s41598-024-64464-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Accepted: 06/10/2024] [Indexed: 07/04/2024] Open
Abstract
The aim of this study was to investigate the primary sites, clinical characteristics, and treatment outcomes of patients with metastatic tumors in the eye and ocular adnexa. This retrospective case series consisted of 42 patients diagnosed with intraocular metastasis (IM) or ocular adnexal metastasis (OAM) at a tertiary center between January 2001 and June 2023. The patients comprised 18 men and 24 women; 24 (57%) and 18 (43%) patients were diagnosed with IM and OAM, respectively. In the IM group, the primary tumors originated from the lungs (79%), followed by the breasts (17%). In the OAM group, the primary tumors originated from the breasts (33%). Previously, 57% of the patients had been diagnosed with cancer. In the IM group, 38% exhibited bilateral involvement. Only 6% of the patients with OAM had bilateral diseases. The 1-, 3-, and 5-year overall survival (OS) was 42%, 18%, and 7%, respectively. The median OS since metastasis diagnosis in the lungs and breast was 11.8 and 10.5 months, respectively. Lung cancer remains the predominant primary cancer in IM, whereas breast cancer is the major cancer in OAM. Despite poor OS, early detection will facilitate the prompt treatment of primary cancer and metastatic sites.
Collapse
Affiliation(s)
- Wantanee Dangboon Tsutsumi
- Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 15, Kanjanavanich Road, Kohong, Hat Yai, Songkhla, 90110, Thailand
| | - Apinya Rattanasuwan
- Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 15, Kanjanavanich Road, Kohong, Hat Yai, Songkhla, 90110, Thailand
| | - Orapan Aryasit
- Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 15, Kanjanavanich Road, Kohong, Hat Yai, Songkhla, 90110, Thailand.
| |
Collapse
|
|
48
|
Ronchetti D, Traini V, Silvestris I, Fabbiano G, Passamonti F, Bolli N, Taiana E. The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers. Cancer Gene Ther 2024; 31:984-994. [PMID: 38493226 PMCID: PMC11257950 DOI: 10.1038/s41417-024-00763-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 03/05/2024] [Accepted: 03/07/2024] [Indexed: 03/18/2024]
Abstract
NONO is a member of the Drosophila behavior/human splicing (DBHS) family of proteins. NONO is a multifunctional protein that acts as a "molecular scaffold" to carry out versatile biological activities in many aspects of gene regulation, cell proliferation, apoptosis, migration, DNA damage repair, and maintaining cellular circadian rhythm coupled to the cell cycle. Besides these physiological activities, emerging evidence strongly indicates that NONO-altered expression levels promote tumorigenesis. In addition, NONO can undergo various post-transcriptional or post-translational modifications, including alternative splicing, phosphorylation, methylation, and acetylation, whose impact on cancer remains largely to be elucidated. Overall, altered NONO expression and/or activities are a common feature in cancer. This review provides an integrated scenario of the current understanding of the molecular mechanisms and the biological processes affected by NONO in different tumor contexts, suggesting that a better elucidation of the pleiotropic functions of NONO in physiology and tumorigenesis will make it a potential therapeutic target in cancer. In this respect, due to the complex landscape of NONO activities and interactions, we highlight caveats that must be considered during experimental planning and data interpretation of NONO studies.
Collapse
Affiliation(s)
- Domenica Ronchetti
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Valentina Traini
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Ilaria Silvestris
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - Giuseppina Fabbiano
- Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Francesco Passamonti
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Niccolò Bolli
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Elisa Taiana
- Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
| |
Collapse
|
|
49
|
Schelz Z, Muddather HF, Jaski FS, Bózsity N, Zupkó I. An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer. Curr Issues Mol Biol 2024; 46:6566-6579. [PMID: 39057033 PMCID: PMC11275392 DOI: 10.3390/cimb46070391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 06/20/2024] [Accepted: 06/24/2024] [Indexed: 07/28/2024] Open
Abstract
Cervical cancer presents a significant challenge to the global health of women. Despite substantial advances in human papillomavirus (HPV)-related cervical cancer vaccines, non-HPV-related cervical cancer is still waiting novel therapeutic options. Drug repurposing has provided a promising approach to improve cancer therapy in recent years. Our study aimed to explore the potential in vitro antineoplastic effects of levosimendan on cervical cancer cells. The antiproliferative effects of levosimendan were investigated on cervical cancer cells using a standard MTT assay. Fluorescent double staining was performed to identify its ability to induce apoptosis and necrosis. The possible mechanism of action of levosimendan was explored using cell-cycle analysis. Furthermore, antimetastatic effects were investigated using a wound-healing assay and a Boyden chamber assay. Our results revealed that levosimendan exhibited the highest growth-inhibitory effect in the HPV-negative C33A cell line. However, the effects were modest compared to the standard agent, cisplatin. Cell-cycle analysis detected that levosimendan can induce cell-cycle arrest in C33A cells by increasing the G1 and G2/M phases, decreasing the S phase, and enhancing the hypodiploid subG1 population. Levosimendan inhibited cell migration and invasion in a concentration-dependent manner. As levosimendan showed antimetastatic efficacy, it could be considered for repurposing to contribute to overcoming resistance to therapy in cervical cancer.
Collapse
Affiliation(s)
| | | | | | | | - István Zupkó
- Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary; (Z.S.); (H.F.M.); (F.S.J.); (N.B.)
| |
Collapse
|
|
50
|
Mayer HF, Coloccini A, Viñas JF. Three-Dimensional Printing in Breast Reconstruction: Current and Promising Applications. J Clin Med 2024; 13:3278. [PMID: 38892989 PMCID: PMC11172985 DOI: 10.3390/jcm13113278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2024] [Revised: 05/23/2024] [Accepted: 05/25/2024] [Indexed: 06/21/2024] Open
Abstract
Three-dimensional (3D) printing is dramatically improving breast reconstruction by offering customized and precise interventions at various stages of the surgical process. In preoperative planning, 3D imaging techniques, such as computer-aided design, allow the creation of detailed breast models for surgical simulation, optimizing surgical outcomes and reducing complications. During surgery, 3D printing makes it possible to customize implants and precisely shape autologous tissue flaps with customized molds and scaffolds. This not only improves the aesthetic appearance, but also conforms to the patient's natural anatomy. In addition, 3D printed scaffolds facilitate tissue engineering, potentially favoring the development and integration of autologous adipose tissue, thus avoiding implant-related complications. Postoperatively, 3D imaging allows an accurate assessment of breast volume and symmetry, which is crucial in assessing the success of reconstruction. The technology is also a key educational tool, enhancing surgeon training through realistic anatomical models and surgical simulations. As the field evolves, the integration of 3D printing with emerging technologies such as biodegradable materials and advanced imaging promises to further refine breast reconstruction techniques and outcomes. This study aims to explore the various applications of 3D printing in breast reconstruction, addressing current challenges and future opportunities.
Collapse
Affiliation(s)
- Horacio F. Mayer
- Plastic Surgery Department, Hospital Italiano de Buenos Aires, University of Buenos Aires Medical School, Hospital Italiano de Buenos Aires University Institute (IUHIBA), Buenos Aires C1053ABH, Argentina; (A.C.); (J.F.V.)
| | | | | |
Collapse
|